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Small GTPases of the Rho family are regulators of cytoskeletal organization, 
neuronal morphogenesis, and transcription and are implicated in the development of 
cancer.  The activity of Rho GTPases is dependent on their binding to GDP (inactive) or 
GTP (active) and is tightly regulated by accessory proteins.  RhoGEFs (Rho guanine 
nucleotide exchange factors) activate Rho GTPases by stabilizing their nucleotide-free 
form via a DH/PH (Dbl homology/Pleckstrin homology) domains module.  Leukemia-
associated RhoGEF (LARG) belongs to a subfamily of RhoGEFs, the RH-RhoGEFs, that 
also contain an RH (Regulator of G protein signaling homology) domain N-terminal to 
v 
the DH/PH domains and specifically activate RhoA, and not the two other RhoGTPases, 
Cdc42 and Rac1.  RH-RhoGEFs are coupled to G protein-coupled receptor (GPCR) 
activation because their RH domains interact with Gα12/13 proteins, which in turn 
activates their GEF activity.  Although the LARG DH domain is sufficient for catalysis 
the PH domain contributes to nucleotide exchange.  To better understand how the LARG 
PH and RH domains contribute to its activity, and to elucidate the structural determinants 
of RhoA-specificity, structures of the LARG DH/PH domains alone and in complex with 
RhoA were determined by x-ray crystallography at 2.1 and 3.2 Å resolution, respectively.  
To verify the structural findings, mutants were generated and assessed using a 
fluorescence assay.  A novel N-terminal subdomain of the DH domain was discovered, 
which seems to be important for activity and might be used as a switch to regulate LARG 
activity.  The sequence of this N-terminal extension is conserved throughout the Lbc 
family of RhoA specific RhoGEFs.  PH domain-assisted nucleotide exchange in LARG is 
dependent on the structural integrity of the junction between the DH and PH domains and 
not on direct contacts of the PH domain with RhoA.  A hydrophobic patch on the PH 
domain has been discovered, which might be a protein-docking site that is used for 
regulation of GEF activity by other proteins (e.g Gα13) or other domains within LARG 
(e.g. RH domain).  Fluorescence assays of fragments including the RH domain showed 
an inhibitory effect of the RH domain in vitro, the structural basis of which will be 
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1.  Introduction 
GTPases and GEFs 
GTPases belong to a large family of eukaryotic as well as prokaryotic proteins 
that have intrinsic GTP hydrolysing ability and share homology with the oncoprotein 
Ras.  GTPases are considered molecular switches because they cycle between an active 
GTP bound and an inactive GDP bound state.  The cycling between the active and 
inactive state is accompanied by subtle structural changes, which are confined to two 
regions, called the switch regions.   
 
Figure 1.1:  Structural differences of inactive GDP-bound and active GTP-bound 
RhoA are confined to the switch regions.  A comparison of GDP and GTP-bound 
RhoA is shown. The structural changes upon activation are confined to switch I /effector 
loop (red) and switch II (blue).  The P-loop (orange) accommodates the phosphate groups 
of the nucleotide.  A Mg2+ (blue sphere) bridges the β- and γ-phosphates.  The Rho-
specific insertion region (yellow) is implicated in effector binding.   
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These changes allow activated GTPases to bind to effector proteins.  Through this 
switch mechanism, GTPases control essential cellular processes from membrane 
transport (Rab, Arf), nuclear transport (Ran), protein elongation (EF-Tu, EF-G), G 
protein-coupled receptor signaling (Gα subunits), to gene expression, cell cycle 
progression, and neuronal morphogenesis (Rho).  Given the importance of GTPases as 
regulators of such diverse and essential cellular processes, their activation state is highly 
regulated.  In the resting state of the cell the spontaneous cycling between the inactive 
GDP bound form and the active GTP bound form proceeds slowly and requires accessory 
proteins for the cell to be able to respond rapidly to changes in the environment.  The 
transformation of GDP-bound GTPases to the GTP-bound form is catalyzed by guanine 
nucleotide exchange factors (GEFs) (Figure 1.2).  Each family of GTPases is regulated 
by its respective family of GEFs (Table 1.1).  Conversely, the intrinsic hydrolysis of GTP 
to GDP by GTPases is accelerated by GTPase activating proteins (GAPs).  
 
Figure 1.2:  GEFs and GAPs control the cycling between inactive GDP-bound and 
active GTP-bound GTPases.  RhoGTPases are molecular switches, which cycle 
between an inactivated GDP bound state and an activated GTP bound state.  The slow 
intrinsic rates of conversion are accelerated by GTPase activating proteins (GAPs) and 
Rho guanine nucleotide exchange factors (RhoGEFs).) 
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GTPase GEF GEF structures 
Ras Cdc25 domain proteins Ras-SOS Cdc25 domain [2] 
 





SOS DH/PH domains [6] 
Vav DH domain [7, 8] 
Trio NDH domain [9] 
β-PIX DH domain [8] 
Rho 
Bacterial RhoGEF SopE Cdc42-SopE [10] 
Ran RCC1 Ran-RCC1 [11] 
Arf Sec7 domain proteins Arf-ARNO Sec7 domain [12] 
Rab Mss4 Mss4 [13] 
EF-Tu EF-Ts EF-Tu-EF-Ts [14] 
Gα subunits GPCR Rhodopsin [15] 
Table 1.1:  GTPase families, their respective families of GEFs and known structures 
of GEFs, either alone or in complex with their effector GTPases.  
 
Although the GEF subfamilies do not share sequence or structural homology, the 
mechanism by which they promote nucleotide exchange seems to be conserved and for 
many GEFs it was shown to involve interference with the nucleotide and magnesium 
binding sites of GTPases and stabilization of the nucleotide free conformation of 
GTPases.  Most kinetic information on the catalysis of nucleotide exchange by GEFs 
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comes from studies with the Cdc25 domain of Sos [16] which exchanges nucleotides on 
Ras, EF-Ts [17-19], the GEF for EF-Tu and RCC1 [20], the GEF for Ran, which is not 
lipid modified.  From these studies it was assumed that the nucleotide exchange reaction 
proceeds through the formation of a quarternary complex of GEF, GTPase, nucleotide, 
and magnesium, that is followed by expulsion of magnesium and nucleotide and the 
formation of a high affinity binary complex of GEF with GTPase (Scheme 1).  This 
assumption was supported by several crystal structures of GEFs in complex with their 
respective GTPases, that all trap the exchange reaction in a nucleotide- and magnesium-
free state.  In some of these structures (e.g. Dbs-RhoA [3], Dbs-Cdc42 [4], Tiam-Rac1 
[5], Intersectin-Cdc42 [3]) the only structural basis for nucleotide expulsion seems to be 
the interference of the GEF with the magnesium binding site, and no interference with 
phosphates, purine, or ribose were seen.  These structures could therefor represent a snap 
shot of an intermediary state of the exchange reaction and not the high affinity binary 
complex.  Other structures (e.g. SOS-Ras [2], EF-Ts-EF-Tu [14], Sec7-Arf [12]) also 
exhibit a conformational change in the P-loop that interferes with phosphate binding.  
These structures confirm the observation from kinetic rate constants that the expulsion of 
magnesium alone cannot account for the nucleotide exchange rates.  It was shown that 
the rate limiting step in the scheme described above is the release of nucleotide from the 
quarternary complex [21].   
The GEF catalyzed reaction (Scheme 1.1) can proceed in both directions, but the 
uni-directional exchange of GTP for GDP in vivo is assumed to be driven by the cytosolic 
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excess (3 to 10 fold [22]) of GTP over GDP as well as by proteins that bind to the 
activated form of the GTPase and shift the equilibrium to the GTP-bound form. 
 
Scheme 1.1:  Kinetic scheme for nucleotide exchange reactions, catalyzed by GEFs.  
GEFs catalyze the exchange of GTP for GDP on GTPases.  Although the exchange 
reaction can proceed in both directions, in vivo it is driven by the concentrations of 
nucleotides and GTPase-binding proteins.  
 
Common structural features of GTPases 
GTPases share about 25% sequence identity between, and 40-80% sequence 
identity within the subfamilies.  The minimal highly conserved domain that is responsible 
for nucleotide binding and hydrolysis is called the G-domain or Ras-like domain, and 
consists of a six-stranded β-sheet and five α helices.  However, GTPases of several 
subfamilies have insertions or extensions compared to Ras (Figure 1.3).  These insertions 
are necessary for the specific function of these subfamily proteins.  For instance, the Gα 
subunits have an independently folding α-helical domain of about 14 kDa that is thought 
to function as an internal GAP, by donating and correctly positioning a catalytic arginine 
[23].   
The nucleotide binding pocket is comprised of highly conserved regions that 
accommodate the phosphate groups (P-loop) and the nucleotide base (116GXKXDL121 
motif, 160SAK162 motif) (Figure 1.4).  All GTPases, except for Gα subunits, bind 
magnesium with high affinity in the GDP and GTP bound state, neutralizing the negative 
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charges on the β and γ phosphates (Figures 1-4).  Removal of the magnesium ion results 
in nucleotide dissociation and the presence of magnesium inhibits nucleotide 
dissociation.  Gα subunits only bind magnesium with high affinity in the GTP bound 
state, but not the GDP bound state.  It is thought that the βγ subunit prevents nucleotide 
dissociation.   
The structural changes that accompany the cycling between GDP- and GTP-
bound form involve two highly conserved regions, the switch I and switch II regions 
(Figure 1.1).  Although the details of the switch mechanism differs in the various GTPase 
families, the basis for the conformational change is universal and involves contacts of the 
γ-phosphate oxygens with the conserved residues Thr37 and Gly62 (Rho nomenclature, 
Fig. 1.4) in switch I and switch II, respectively.  Hydrolysis of GTP causes a release of 
these contacts and the two switch regions change into a relaxed conformation.  The 
transition from active to inactive GTPase has therefore been termed a “loaded-spring” 
mechanism [24]. 
Many GTPases are lipid-modified at their N- or C-termini, which is not only 
important for membrane localization, but also for protein-protein interactions and 
regulation [25].  For example, only geranyl-geranylated RhoA can be sequestered in the 
inactive GDP bound state in the cytosol by interaction with RhoGDI.  SOS catalyzes 
nucleotide exchange more efficiently on prenylated K-Ras [26].  Likewise, RhoGEFs are 
more active on prenylated Rho than its unprenylated form [27-29].  Gα13 can only 
activate Rho-dependent signaling when it is palmitoylated [30].  
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Figure 1.3: Sequence alignment of small GTPases.  Highlighd are common structural 
features of small GTPases and the effector loop of RhoA.  The sequence alignment was 
performed with the program Clustal W [31] and corrected manually according to 
structural alignment.  Accession numbers of sequences used for the alignment 
are:RhoA3237320, Cdc42 16357472, Rac1 22043610, K-Ras 417590, Ran 32425497, 
Arf1 4502201, Rab 6679587. 
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Figure 1.4: The nucleotide binding pocket of RhoA.  The nucleotide and Mg 2+ binding 
pockets of RhoA are comprised of residues from the switch I and switch II regions, as 
well as the P-loop, the 160SAK162 motif and the 116GXKXDL121 motif.   
 
Rho GTPases and RhoGEFs 
Rho GTPases are Ras homology proteins that regulate the actin cytoskeleton, 
gene expression, and cell cycle progression [32].  Members of the three RhoGTPase 
subfamilies Rho, Cdc42, and Rac share 40 % sequence identity.  The Rho subfamily was 
the first to be discovered and it has three homologous isoforms, RhoA, RhoB and RhoC, 
which share 85 % sequence identity.  Structurally, Rho GTPases differ from other 
GTPases by having a 13 amino acid α-helical insertion (Fig. 1.1, 1.3) that is implicated in 
effector binding [33, 34] and regulation by the regulatory Rho GDIs (guanine nucleotide 
8 
dissociation inhibitors), which keep Rho GTPases in the inactive state [35].  Rho 
GTPases are geranylgeranylated at the N-terminus, which is important for some of their 
functions [36, 37] and for proper membrane localization. 
Rho, Cdc42, and Rac exert different morphological effects on the cytoskeleton 
[38] and promote transcription through different signaling pathways [39].  However, 
there is evidence that the signaling cascades of the three individual RhoGTPase 
subfamilies are functionally linked [40] and the response of Rho GTPases to extracellular 
stimuli is a result of a complex signaling network involving proteins from all three 
subfamilies.  The Rho GTPase signaling network is also connected to the oncoprotein 
Ras through SOS, which carries domains that catalyze nucleotide exchange on Ras as 
well as Rac1 [41] (Table 1).  Rho GTPases have been identified as downstream effectors 
of the oncogene Ras and are ascribed an essential role in Ras-induced tumorigenesis [42].  
Rho GTPases are activated by the Dbl (Diffuse B-cell lymphoma) family of 
RhoGEFs.  Dbl was the first RhoGEF of this family to be discovered and was initially 
identified as an oncoprotein [43].  Since then, approximately 50 related RhoGEFs have 
been identified in the human genome [44] and together they are the largest family of 
related oncoproteins.  Most RhoGEFs have a tandem Dbl homology/pleckstrin homology 
(DH/PH) domain module that is responsible for their GEF activity.  Individual 
subfamilies of RhoGEFs contain additional domains, through which they are thought to 
receive signals from various receptors and regulatory proteins [45].  How and if these 
additional domains contribute to the exchange activity is not well understood.  Recently a 
bacterial RhoGEF from Salmonella typhimurium, SopE, has been discovered, which is 
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the first known RhoGEF that does not contain a DH domain [46].  SopE has an entirely 
different structure from the DH/PH domains, although the conformation of Cdc42 bound 
to SopE is very similar to that of RhoGTPases in complex with DH/PH domains [10].  
 
RH domain-containing RhoGEFs and LARG 
Leukemia-associated RhoGEF (LARG) belongs to a family of regulator of G 
protein signaling homology (RH) domain-containing RhoGEFs (RH-RhoGEFs), which 
are regulated by Gα12/13-coupled receptors (Figure 1.5).  RH domains were initially 
identified as negative regulators of G protein signaling processes, because the largest 
subfamily of RH domain proteins, the RGS proteins, accelerate the intrinsic GTP 
hydrolysis of Gα subunits by stabilizing its transition state [47].  RGS proteins were 
therefore termed GTPase activating proteins (GAPs) for the Gα family.  Several RH 
domains with various levels of specificity or promiscuity for the four families of Gα 
subunits have been discovered.   
LARG and the two other members of the RH-RhoGEF family, PDZ-
RhoGEF/GTRAP48 and p115RhoGEF/Lfc, selectively activate RhoA and do not act on 
Rac1 or Cdc42 [48-50].  LARG has an additional amino-terminal PDZ (PSD-95/Dlg/ZO-
1) domain (Fig. 1.6) that interacts with the carboxyl-termini of the non-phosphorylated 
insulin-like growth factor receptor [48] and the transmembrane protein Plexin-B1 [51].  
Through Plexin-B1 signaling, LARG is involved in growth cone collapse during nerve 
cell development.  LARG was discovered as an N-terminally truncated form 
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that was fused to the gene MLL (myeloid-lymphoid lineage leukemia) in a patient with 
acute myeloid leukemia [52] (Fig. 1.6).  MLL is commonly involved in chromosomal 
translocations leading to the generation of childhood and drug-induced leukemia [53].  
The predicted translation product of the MLL-LARG fusion lacks the amino-terminus of 
LARG including the PDZ domain, and the Zinc-finger domains of MLL (Fig. 1.6).  It is 
not known, however, if there is a correlation between aberrant LARG activity and the 
development of leukemia.  Two observations suggest that the intracellular concentration 
of an N-terminally truncated form of LARG is increased and that this could lead to de-
regulation of RhoA activity.  Firstly, higher expression levels of amino-terminally 
truncated forms of LARG compared to full length LARG are seen in vivo [54].  
Secondly, putative PEST sequences have been identified in the LARG amino terminus 
[54] and the truncated LARG lacking these sequences could be less prone to degradation 
by the ubiquitin pathway.  Increased intracellular LARG levels might lead to downstream 
deregulation and this might be a cause for the involvement of LARG in leukemogenic 
cell development.   
Besides its implications in the generation of leukemia, LARG might also play a 
central role in RhoA-mediated oncogenic transformation by Gα12 family proteins (i.e. 
Gα12 and Gα13).  The RH domain of LARG binds to and acts as a GAP on the oncogenic 
Gα12/13 subunits.  The binding of activated Gα13 increases the nucleotide exchange 
activity of the DH/PH domains [55].  Activation of LARG by Gα12 requires tyrosine 
phosphorylation of LARG [55].  Investigations of the mechanism by which Gα13 
interacts with RH-RhoGEFs have been undertaken, using p115RhoGEF as a prototype 
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RH-RhoGEF.  Two possible models of activation have been proposed.  Based on early 
experiments that showed an increased GEF activity of a construct lacking the RH 
domain, an auto-inhibitory role of the RH domain on the DH/PH domains has been 
assumed [56].  However, later experiments with prenylated RhoA showed decreased 
activity when the RH domain was removed [57, 58].  Based on studies that identified a 
binding site for Gα13 within the C-terminus of LARG, including the DH/PH domains, 
direct binding of Gα13 to the DH/PH domains, in addition to the RH domain, might 
allosterically enhance GEF activity [58].  
12 
 
Figure 1.5:  Model of signaling from GPCRs to RhoA.  A signal (e.g. thrombin or 
lysophosphatidic acid) activates the Gα12-coupled receptor, which in response activates 
the Gα12 family proteins (i.e. Gα12 and Gα13).  Binding of the activated Gα12 family 
proteins to the RH domain of RH-RhoGEFs leads to enhanced activity of the DH/PH 
domains, which exchange GTP for GDP on RhoA.  Activated RhoA, through various 
effectors, regulates the cytoskeleton as well as transcription from the serum response 
element (SRE).  The molecular mechanism by which the RH, DH and PH domains of 
RH-RhoGEFs coordinately transduce signals from Gα12 to RhoA is unknown.   
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Figure 1.6: LARG has been discovered as a gene fusion with MLL.  The MLL-LARG 




The long-term goal of this project is to understand the molecular mechanisms of 
signaling from oncogenic Gα12/13 to LARG and RhoA, and in particular how the 
individual domains of LARG coordinate its activity and regulation.  Knowledge gained 
from this study will not only increase our understanding of the organization of modular 
proteins but also can ultimately be used for structure based design of drugs that interfere 
with tumorigenic and metastatic cell development.  Furthermore an understanding of the 
domain structure and organization of LARG will be helpful in explaining a potential role 
for LARG in the etiology of leukemia.  
 
This research study initially focused on the structural characterization of the 
interaction between Gα12/13 and the RH domain of LARG (Chapter 2).  A structure of 
either the Gα13 or Gα12 subunit by itself would be of great interest because of the 
oncogenic potential of this Gα subfamily.  Chapter 2 describes attempts to express 
Gα12/13 in a functional form and with large yields from E. coli.  Furthermore, attempts are 
described to purify and crystallize an LARG RH-Gα13 complex and a complex of the RH 
with the DH/PH domains.  The structure determination of these proteins, however, was 
hindered by the lack of an appropriate large-scale expression system for Gα12/13 subunits 
and by the unsuccessful attempts to crystallize the LARG RH domain.  This led to a shift 
in focus to the interaction of the LARG DH/PH domains with its substrate RhoA and 
resulted in the structure determination of the DH/PH domains and their complex with 
RhoA (Chapter 3).  The focus of Chapter 3 was to answer three questions about the 
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molecular biology of LARG.  (a) What is the structural basis of the specificity for the 
RhoA subfamily?  (b) Can the structures reveal a role for the PH domain in RhoA 
binding and/or nucleotide exchange?  (c) Can the structures reveal possible docking sites 
for Gα13 or the RH domain on the DH/PH domains?  Structural findings are 
complemented by steady state kinetic assays of various LARG fragments and DH/PH and 
RhoA mutants that were designed based on structural analysis (Chapter 4).  Results from 
structural and functional analyses taken together reveal novel aspects of the role of the 
RH and the PH domains in the GEF activity of LARG.  Results from Chapters 3 and 4 
are discussed and integrated into a model describing the molecular mechanisms involved 
in signal transduction from LARG to RhoA, and future experiments that need to be 








The family of Gα12 subunits has two members, Gα12 and Gα13, which share 67% 
sequence identity.  They were first identified in a search for G proteins with transforming 
potential [59].  Two observations suggested that Gα12/13 might be upstream regulators of 
Rho GTPases.  First, the expression of constitutively activated mutants of Gα12/13 and 
RhoA shows a similar phenotype.  Second, the Clostridium botulinum C3 exoenzyme, 
which inactivates Rho GTPases by ADP ribosylation [60], also inhibits Gα12/13 induced 
effects [61].  However, the signaling events that transduce signals from Gα12/13 to Rho 
GTPases only became evident when it was discovered that Gα13 directly stimulates 
nucleotide exchange on the RH-RhoGEF, p115RhoGEF [56].  RH-RhoGEFs contain and 
RH domain in addition to the DH/PH domain module.  Three members of the family of 
RH-RhoGEFs have been identified: LARG, PDZ-RhoGEF/GTRAP48 and 
p115RhoGEF/Lsc, which were all found to activate RhoA, but not Rac1 or Cdc42 [49, 
50, 54].  The RH domain of p115RhoGEF specifically binds to and acts as a GAP on 
Gα13 and to a lesser extent on Gα12 subunits[62].  Furthermore, Gα13, but not Gα12 
binding to p115RhoGEF increases its nucleotide exchange activity.  Similar result 
showing differential activity of Gα13 and Gα12 have been found for LARG [55].   
However, the mechanism by which Gα13 relays signals to RH-RhoGEFs remains largely 
unknown.  Although early studies with p115RhoGEF indicated that the RH domain auto-
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inhibits the DH/PH domains until Gα13 binds [56], later experiments showed that 
truncation of the RH domain lead to decreased GEF activity [57, 58].  Furthermore, an 
additional Gα13 binding site within a fragment containing the DH/PH domains was 
discovered, therefore suggesting a complex allosteric mechanism of activation.  In this 
model, the RH domain either directly increases the GEF activity of the DH domain or 
associates with another region in the RH-RhoGEF, which allosterically increases the DH 
domain activity [58].   
Studies with LARG and PDZ-RhoGEF suggest that separate positive feedback 
loops might be involved in the overall response of RH-RhoGEFs to extracellular signals.  
For these proteins it has been shown that additional indirect routes of activation are 
possible.  LARG and PDZ-RhoGEF are both substrates for tyrosine phosphorylation by 
focal adhesion kinase (FAK) [63], which is a downstream effector of Gα12/13 and Gαq 
coupled receptors.  In PDZ-RhoGEF it was shown that the region that is responsible for 
phosphorylation lies C-terminal to the DH/PH domains, and that phosphorylation leads to 
increased RhoA activation [63].  In a different study, tyrosine phosphorylation of LARG 
by Tec kinase has been shown to make it responsive to Gα12 activation, while it does not 
increase GEF activity in response to Gα13 [55].  Interestingly, LARG, but not 
p115RhoGEF or PDZ-RhoGEF, also enhances RhoA activation in response to Gαq [64].  
 
Objectives 
 This chapter describes work towards the structure determination of the LARG RH 
domain, Gα13 and the RH-Gα13 complex.  We focused on the expression of Gα13 rather 
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than Gα12 because functional studies of the interaction of Gα13 with p115RhoGEF have 
already yielded some information about the molecular mechanisms involved in activation 
of RH-RhoGEFs by Gα13.  These structures in conjunction with sequence comparison 
would help answer the following questions: (1) What are the molecular determinants for 
specific recognition of Gα12/13 by the LARG RH domain?  (2) What are the structural 
features of Gα13 that explain (a) lower GAP activity of the LARG RH domain on Gα12 
compared to Gα13, and (b) inability of AlF4- activated Gα12 to activate the GEF activity 
of LARG in vitro?  
The major obstacle in addressing these questions is the production of suitable 
quantities of Gα13, which is necessary for the screening of crystallization conditions.  
Gα12 and Gα13 are mammalian proteins that are post-translationally modified at their N-
termini (singly and dually palmitoylated, respectively) and membrane associated.  
Unmodified Gαs, Gαi, and a Gαit chimera have been expressed in E. coli and their 
structures have been determined [65-67].  Although Gα12 and Gα13 have been expressed 
using the eukaryotic baculovirus expression system in Sf9 insect cells, this purification 
yields less than 100 µg per liter of cell culture [68].  The development of a large-scale 
expression system for Gα13 from E. coli would therefore be a major contribution to 
studies of the molecular and structural biology of these proteins.  Several approaches 
have been taken in this study.  (1) Gα13 was expressed from modified pMALc2X vectors 
as fusion proteins with maltose binding protein (MBP).  MBP has been previously shown 
to enhance the solubility of its fusion partners and has been termed a molecular 
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chaperone [64, 69].  (2) An N-terminally truncated form of Gα13, ∆N47-Gα13, was 
expressed.  From structural analyses of other Gα proteins this region is known to form a 
highly mobile α helix that could, in theory, hinder crystallization.  (3) Purifications were 
performed in the presence of detergents to mimic a membrane environment, even though 
Gα subunits are not post-translationally modified in E.coli.  (4) Purifications were 
performed in the presence of AlF4- and GDP.  In the AlF4-•Gα•GDP complex, AlF4- 
forms a square planar complex that is axially coordinated to a β-phosphate oxygen and to 
a water molecule [66].  A similar coordination (trigonal bi-pyramidal) is assumed for the 
γ-phosphate at the transition state of the nucleophilic attack by an activated water 
molecule. AlF4- and GDP are therefore used as an analog to mimic the transition state for 
the intrinsic GTP hydrolysis of Gα subunits.  Binding of AlF4- or GTP to Gα subunits is 
associated with movements of the switch regions from a solvent exposed to a more 
compact, buried environment.  (5) Purifications were performed in the presence of the 
LARG RH domain and AlF4-.  RH domains are known to bind and stabilize preferentially 
the AlF4- activated form of Gα subunits [70].  (6) MBP-Gα13 (86 kDa) was co-expressed 
with the chaperonins GroEL and GroES.  GroEL and GroES are the major chaperonins 
involved in protein folding.  The majority of GroEL substrates is smaller than 60 kDa and 
contains multiple αβ domains.  However, successful purification of proteins that are 
larger than 60 kDa when co-expressed with GroEL/GroES has been reported [71, 72].  
Although it is unlikely that the chaperonin is directly involved in proper folding of these 
proteins, it is possible that accessory proteins that help with folding, are stabilized. 
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2.2 Methods 
2.2.1 Cloning, Expression and Purification of the LARG RH domain  
 
 
Figure 2.1: Vector map of the expression vector for the LARG RH domain, 
pMALc2T_EcoRI_RH_H6.  The LARG RH domain is expressed as an N-terminal 
fusion protein with maltose binding protein (MBP) and a C-terminal H6 tag.  After 
cleavage with TEV protease the RH domain contains additional three amino acids at the 
N-terminus and four amino acids followed by an H6 tag at the C-terminus.  Arrows 
indicate the start of the coding regions for the Ptac promotor (Ptac), Lac repressor (lacIq), 




The LARG RH domain (residues 341-562) was inserted into a modified 
pMALc2X vector (New England Biolabs) using EcoR I and Sal I restriction sites.  The 
modified vector (pMALc2TEcoR IH6) was generated by replacing the factor Xa protease 
cleavage site with that of tobacco etch virus (TEV) protease, and inserting a sequence 
that encodes for a C-terminal hexahistidine (H6) tag followed by a stop codon.  The 
pMALc2X vector was first digested with restriction enzymes Ava I and EcoR I.  5' 
phosphorylated oligonucleotides encoding the TEV protease cleavage site 
(tcggggaaaacctgtattttccagggcg and aattcgccctgaaaatacaggttttcc, Integrated DNA 
Technologies) were mixed in equimolar amounts, heated to 80 ºC for 10 min, allowed to 
cool and ligated with the digested pMALc2X vector using T4 DNA ligase  (Sigma).  To 
insert the sequence for the C-terminal H6 tag, the vector was then digested with the 
restriction enzymes Sal I and Hind III, and complementary oligonucleotides 
(tcgacggaggtcaccaccaccaccaccactaaa and agcttttagaggaggaggaggaggagacctccg, Integrated 
DNA Technologies) were inserted as described above. 
The RH domain fragment of LARG was expressed using the E. coli strain 
Rosetta (DE3) pLysS (Novagen), which carries a plasmid that supplies t-RNAs for six 
codons rarely used in E. coli.  Cells were grown in Luria-Bertani (LB) media, 
supplemented with 0.2% α-D-glucose, 50 µg/ml carbenicillin, and 34 µg/ml 
chloramphenicol at 37 °C to an OD600 of 0.6.  Protein expression was induced with 
10 µM isopropylthiogalactopyranoside (IPTG) at 20 °C and cells were harvested after 24 
hours by centrifugation at 3500 rpm in a Beckman Coulter Avanti J-20 centrifuge using a 
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JLA 8.100 rotor.  The cell pellet was frozen in liquid nitrogen and stored at –80ºC until 
purification.  
Cells were lysed with lysozyme (1 mg/ml) (Sigma) in lysis buffer (20 mM 
HEPES pH 8.0, 300 mM NaCl, 10 mM β-mercaptoethanol (βME), 10 mM imidazole pH 
8.0) supplemented with 0.3 mM EDTA and protease inhibitors (1 µM leupeptin, 1 mM 
lima bean trypsin inhibitor, 1 mM PMSF, and 1 mM TPCK).  Lysates were treated with 
20 µg DNaseI (Sigma) per gram of cell pellet and centrifuged for 45 min at 35000 rpm in 
a Beckman Coulter Optima LE-80K ultracentrifuge, using a Type 45 Ti rotor.  The 
supernatant was loaded onto a drip column containing immobilized Nickel resin (Ni-
NTA Superflow, Qiagen), which was pre-equilibrated with lysis buffer.  After washing 
with 5 column volumes of lysis buffer and 5 column volumes of wash buffer (lysis buffer 
with 20 mM imidazole), protein was eluted in 1 ml fractions with elution buffer (lysis 
buffer with 250 mM imidazole).  Fractions containing the MBP-RH fusion protein were 
pooled and dialyzed overnight against dialysis buffer (20 mM HEPES pH 8.0, 300 mM 
NaCl, 5 mM βME) in the presence of 1% (w/w) TEV protease.  The RH domain was 
separated from cleaved MBP by nickel-affinity chromatography as described above for 
the fusion protein.  Fractions containing the RH domain were pooled, concentrated, and 
loaded onto a size exclusion chromatography column (S200 16/60, Amersham Pharmacia 
Biotech), which was pre-equilibrated with gel filtration buffer (20 mM HEPES pH 8.0, 
100 mM NaCl, 1 mM DTT).  The LARG RH domain elutes as a monomer of 
approximately 25 kDa.  Fractions containing the RH domain were pooled, concentrated 
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to approximately 15 mg/ml and stored at -80 ºC.  The typical yield was 7 mg protein per 
liter of cell culture.  
 
2.2.2 Expression and Purification of Gα13 from Sf9 cells 
Gα13 was first expressed from Sf9 cells, following a protocol by Kozasa [68].  In 
this procedure Gα13 is expressed in a hetero-trimeric complex with Gβ1, and H6-Gγ2.  The 
H6 tag on Gγ2 allows affinity purification of the complex on a Ni-NTA column.  Gα13 can 
subsequently be separated from the Gβ1H6-Gγ2 heterodimer by activating Gα13 with the 
transition state analog AlF4-.  Dr. Kozasa (University of Illinois at Chicago Medical 
Center) provided us with the Gα13, Gβ1, and H6-Gγ2 baculoviruses.  Sf9 cells were 
maintained at about 1x106 cells per ml were expanded to 250 ml in IPL-41 medium 
containing 10% fetal bovine serum in a 500 ml flask.  After the cell density reached about 
6 x 106 cells per ml (about two to three days) the cell culture was diluted to 1 x 106 cells 
per ml by expansion to 1 L in four 250 ml cultures in four 500 ml flasks.  After two days, 
cells were further expanded to six 1 L cultures grown in six 2 L flasks in IPL-41 media, 
substituted with 1% fetal bovine serum and 1% lipid mix (invitrogen).  After one day, 
cells were infected with amplified recombinant baculoviruses encoding Gα13, Gβ1 and 
Gγ2 containing a N-terminal H6 tag.  The virus stock solutions were titered to 4 x 108 
pfu/ml and cells were infected with 5 multiplicity of infection units (MOI, plaque 
forming units (pfu) per cell) for Gα13, 3.75 MOI for Gβ1 and 2.5 MOI for H6-Gγ2.  After 
48 hours, cells were harvested by centrifugation in a Beckman Coulter Avanti J-20 
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centrifuge using a JLA 8.100 rotor and cell pellets were frozen in liquid nitrogen.  
Purification was performed essentially as described by Kozasa [68].  The cell pellet from 
4 l was suspended in 600 ml lysis buffer, dounced, and centrifuged at 700 g for 10 min, 
which removes intact cells and nuclei.  The supernatant was then centrifuged at 35000 
rpm for 30 min.  The supernatant of this spin was removed and saved for further analysis.  
The pellet, which contains cell membranes and the membrane bound heterotrimeric 
Gα13β1H6-γ2 complex was re-suspended in 300 ml wash buffer, containing 1 mM MgCl2 
and 10 µM GDP.  After an additional centrifugation at 35000 rpm for 30 min, the pellet 
was re-suspended in 200 ml wash buffer.  Protein concentration determination by the 
Bradford method showed 400 mg total protein.  Kozasa et al. report a yield of 1.2-2g of 
protein from an equivalent volume of Sf9 cell culture at this step.  Membranes were 
frozen by pouring them into liquid nitrogen, and stored at –80°C until the next step of 
purification.  Sodium cholate was added to 1% to extract the heterotrimeric Gα13β1H6-γ2 
complex from the membranes and the solution was stirred on ice for 1 hr in the presence 
of protease inhibitors.  After centrifuging at 35000 rpm for 40 min, the supernatant was 
filtered through a 0.2 µm filter and diluted to 1 mg/ml with buffer containing 1 mM 
MgCl2, 10 µM GDP, and 0.5% Thesit.  Subsequently, the solution was loaded onto a 
NiNTA column and washed with buffer containing an additional 10 mM imidazole.  The 
column was then moved from 4°C to room temperature and washed with buffers 
containing 0.3 % and 1 % β-octoglucoside, successively.  The column was then moved to 
30°C and Gα13 was eluted in 1 ml fractions with buffer containing 1 % β-octoglucoside 
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and 30 µM AlF4-.  AlF4- acts as a transition state analog and releases Gα13, while the 
β1H6-γ2 complex remains bound to the NiNTA resin.  The β1H6-γ2 complex was then 
eluted in 1 ml fractions with buffer containing 150 mM imidazole.  
 
2.2.3 Cloning, Bacterial Expression and Purification of Gα13  
Gα13 (residues 1 to 377) was amplified from a pCMV5- Gα13 vector (a gift from Dr. 
Kozasa, University of Illinois at Chicago, Medical Center) and inserted into the 
pMALc2XH6 (see 2.2.1) and pMALc2TH6 (see 3.2.1) expression vectors, using BamH I 
and Sal I restriction sites. An expression study with the following expression strains 
BL21 (DE3)RP, BL21 (DE3)RIL, TB1, HMS174 (DE3) pLysS, and BL21 (DE3)RP 
showed slightly higher expression levels in HMS174, which was then chosen as the 
expression strain.  Later protein expressions were done in the strain Rosetta (DE3) pLysS 
(Novagen).  Protein expression was induced with 10 or 100 µM ITPG at 20°C for 20 
hours, and purifications were performed as described for the DH/PH domains in 3.2.1, 
except that lysis buffer additionally contained 50 µM GDP, 50 µM aluminum chloride, 
10 mM sodium fluoride, and either 0.2% Triton X 100, or 0.5% Thesit.  Magnesium 
chloride was added to a final concentration of 5 mM after lysis was completed, as it is 
known to stabilize bacterial cell membranes.  Buffers for affinity and gel filtration 
columns contained 1% β-octyl-glucoside instead of Triton X100 or Thesit.  
 
Cloning, expression and purification of an N-terminally truncated construct of Gα13 
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Gα13 constructs that lacks 47 amino acids at the N-terminus and do or do not have 
a stop codon at the C-terminus were cloned into the pMALc2XH6 plasmid, which was 
generated as described in 2.2.1, using BamH I and Sal I restriction sites.  The Gα13 
constructs expressed from these vectors either had an H6 tag and were purified under 
various conditions on NiNTA columns, or did not contain an H6 tag and were purified on 
amylose columns and used for binding studies with the H6-tagged RH domain (see next 
section).  Both proteins were expressed from strain HMS174 (DE3) pLysS or Rosetta 
(DE3) pLysS.   
 
Figure 2.2: Vector map of the expression vector for Gα13, 
pMALc2T_BamHI_Gα13_H6.  Gα13 is expressed as an N-terminal fusion protein with 
maltose binding protein (MBP) and a C-terminal H6 tag.  After cleavage with TEV 
protease Gα13 contains additional two amino acids at the N-terminus and four amino 
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acids followed by an H6 tag at the C-terminus.  Arrows indicate the start of the coding 
regions for the Ptac promotor (Ptac), Lac repressor (lacIq), β-lactamase (AmpicillinR), 
and maltose binding protein (malE).    
2.2.4 Assessment of correctly folded and active Gα13 
MBP-Gα13-RH complex formation 
We attempted to form an MBP-Gα13•RH domain complex, in order to stabilize 
Gα13 during digestion from MBP and to purify this complex for crystallization.  A 
protocol for the formation of a complex between Gαi and RGS4 [73] was followed.  
MBP-Gα13 was activated with AlF4- by incubation for 15 min at 4°C in complex buffer 
containing 20 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT, 12 µM GDP, 5 mM 
MgCl2, 50 µM AlCl3, and 5 mM NaF.  Subsequently, 1.5 molar excess of the LARG RH 
domain was added and the solution was incubated for an additional 15 min on ice.  The 
mixture was subjected to gel filtration in complex buffer or complex buffer containing 
1% β-octyl-glucoside on Superdex 75 and 200 columns arranged in tandem and 0.5 ml 
fractions were collected.  
 
MBP-∆N47Gα13-RH complex formation 
Complex formation of ∆N47Gα13 with the LARG RH domain was performed on 
a NiNTA column (Qiagen).  The LARG RH domain, containing a C-terminal H6 tag was 
loaded onto a NiNTA column that was pre-equilibrated with buffer containing AlF4-.  A 
1.6 fold molar excess of MBP-∆N47Gα13 was incubated with the beads for 12 hours at 
4°C. Subsequently, protein was eluted with buffer containing 250 mM imidazole pH 8.0.  
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Trypsin protection assay 
Trypsin protection assays were done in the presence of 30 µM AlF4- or 300 µM 
GTPγS with 0.01-2% (w/w) trypsin (Calbiochem) at 37°C.  The time course of digestion 
could be best observed with 0.01% trypsin.  Samples were taken at time points 10, 30 and 
60 minutes.  Trypsin digests where performed on the MBP-∆N47Gα13 fusion protein and 
on Gα13 or ∆N47-Gα13.  When trypsin protection assays were performed on the fusion 
proteins, protein concentrations were high enough for visualization with Coomassie 
Brilliant Blue staining.  However, when performed on the free Gα13 or ∆N47-Gα13, 
western blots had to be performed with a specific Gα13 antibody (Santa Cruz), which 
recognizes the N-terminus of Gα13, or with a common antibody for Gα subunits (NEN), 
which recognizes the highly conserved GAGE sequence in the nucleotide binding site.  
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2.3. Results and Discussion 
Expression and Purification of Gα13 from Sf9 cells 
Gα13 was purified from Sf9 insect cells, following a protocol by Kozasa [68]. 
Both Gα13 and Gβ1H6-γ2 were barely visible on a gel stained with Coomassie Brilliant 
Blue (Figure 2.4), and only a total amount of about 130 µg of Gα13 was detected and 60 
µg of Gβ1H6-γ2 by the Bradford method.  Kozasa reported a yield of 400 µg of Gα13 from 
an equivalent size cell culture.  Western blots, performed with antibodies that recognize 
Gβ1 and the N-terminus of Gα13 appeared to only detect background.  A problem with 
the methodology of the Western blot was likely the reason for the failed detection.  It was 
therefore never convincingly shown that Gα13 and Gβ1H6-γ2 were expressed in Sf9 cells.  
Possible reasons for low yields of G proteins from Sf9 insect cell membranes are Sf9 
cells that were overgrown, or there was incomplete lysis of cell membranes during 
purification, or deficient virus stock solutions [68].  Furthermore, excessive 
overexpression of H6-γ2, which usually shows the highest expression levels in Sf9 cells, 
can inhibit the expression of Gα subunits [68].  For the screening of crystallization 
conditions it is estimated that an initial 10 mg of protein are necessary, which would be 
sufficient for fourty 24 well hanging drop crystal trays, or 960 different crystallization 
conditions.  If a yield of 400 µg per 6 L cell culture could indeed be achieved, expression 
of Gα13 from Sf9 insect cells would require one to grow and process at least 150 liters of 
cell culture, which is not very economical. 
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Figure 2.4:  Purification of Gα13 from Sf9 cells.  Sf9 cells infected with Gα13, Gβ1, and 
H6-γ2 baculoviruses were harvested and lysed.  The membrane fraction was isolated and 
the Gα13β1H6-γ2 complex was extracted from the membrane with 1% sodium cholate.  
After centrifugation the supernatant was loaded onto a NiNTA column.  Gα13 was eluted 
with buffer containing 30 µM AlF4-.  The Gβ1H6-γ2 complex was eluted with buffer 
containing 150 mM imidazole.  Samples of the eluted fractions were loaded on an SDS-
PAGE gel and stained with Coomassie Brilliant Blue.  S: supernatant of Gα13β1H6-γ2 
cholate extraction from membranes, P: pellet, FT: flow through, W: wash.   
 
Expression and Purification of Gα13 from E. coli  
Independent of the various conditions that were explored for expression and 
purification of Gα13 from E. coli, usable amounts of Gα13 could not be produced and the 
following problems were observed:  (1) Incomplete and unspecific digestion of fusion 
proteins with factor Xa or TEV protease (Figures 2.5 and 2.6).  This was particularly 
evident for the MBP-∆N47-Gα13 fusion protein, for which complete digestion could not 
be achieved even with 10% (w/w) TEV protease (Figure 2.6).  It is possible that the 
flexible N-terminal extension of Gα13 is necessary for proper access of TEV protease to 
its cleavage site in the MBP-∆N47-Gα13 fusion protein, because digestion of full-length 
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Gα13 with TEV protease appeared to work better although it was still not complete 
(Figure 2.5).  Typically, MBP fusion proteins are cleavable with 1-3 % TEV protease.  
Incomplete digestion likely indicates that although some fusion protein might be folded 
correctly, most of the fusion protein is misfolded and aggregated and access to the 
protease cleavage site is impeded. 
 
Figure 2.5:  Purification of MBP-Gα13.  MBP-Gα13 was expressed in the E. coli strain 
BL21 (DE3) pLysS carrying a plasmid that encodes for the chaperonins GroEL and 
GroES.  Cells were lysed with lysozyme, centrifuged, and the lysate was applied to a 
NiNTA column (NiNTA1).  MBP-Gα13 was eluted with 250 mM imidazole, digested  
with 2 % (w/w) TEV protease, and the digest was subjected to a second NiNTA column 
(NiNTA2).  After washing, protein was eluted from the column with 250 mM imidazole.  
Samples of the various steps in purification of MBP-Gα13 were subjected to SDS-PAGE 
and gels were stained with Coomassie Brilliant Blue.  S: supernatant, P: pellet, FT: flow 
through, W: wash, E: eluate, D: digest. 
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Figure 2.6: Incomplete digestion of MBP-∆N47-Gα13.  MBP-∆N47-Gα13 was 
expressed in the E. coli expression strain Rosetta (DE3) pLysS (Novagen) at 20° C with 
100 µM IPTG for 19hrs.  The cell lysate was subjected to an amylose resin (New 
England Biolabs) and MBP-∆N47-Gα13 was eluted with buffer containing 10 mM 
maltose.  Digests with the indicated amount of TEV protease for 12 hrs did not result in 
complete digestion of the fusion protein.  
 
(2) The fusion proteins (86 kDa) eluted from the gel filtration column in the void volume, 
which is indicative of aggregated protein.  (3) Gα13 eluted from the gel filtration column 
at a molecular weight of approximately 80 kDa (Figure 2.7).  This could be indicative of 
a Gα13 dimer, which would be around 86 kDa.  However, dimerization of Gα subunits 
has not been observed previously and it is more likely that this represents misfolded 
protein.  (4) Although the yield of the MBP-Gα13 fusion protein was high (approximately 
5-10 mg per liter cell culture), the yield of Gα13 after digestion was low (approximately 




Figure 2.7: Gel filtration of the digested MBP-Gα13-H6 fusion protein and Western 
blot of peak fractions.  The TEV digest of MBP-Gα13-H6 was subjected to a NiNTA 
resin (Qiagen), Gα13 was eluted and subjected to two sequentially connected gel filtration 
columns (Superdex 200, Amersham Pharmacia).  Gα13 eluted from the column in an 
80 kDa peak at a flow rate of 0.5 ml/min.  The insert shows a Western blot of fractions 
from the gel filtration run, probed with an N-terminal antibody (sc-410, Santa Cruz).   
 
(5) Two bands just below and just above the 25 kDa standard marker were observed in all 
purifications of MBP-Gα13, independent of the expression cell line, and the purification 
conditions (Figure 2.5).  Only the band just below 25 kDa was also observed in the 
purification of MBP-∆N47Gα13 (Figure 2.8).  Both bands could not be detected in a 
western blot with an antibody directed against the N-terminus of Gα13.  These proteins 
bound to NiNTA resin and to a cation exchange resin  and could therefore be C-terminal 
fragments of Gα13.  The expressed Gα13 construct contains a C-terminal H6 tag.  Gα13 has 
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two domains, a Ras-like domain and an α helical domain, that is inserted between the α1 
helix and β2 strand of the Ras-like domain.  In addition Gα13 has an N-terminal helix of 
47 amino acids length.  A possible digestion product of full length Gα13 could yield 
fragments of approximately 27.6 and 14 kDa, corresponding to the Ras-like and α helical 
domain, respectively.  Additional digestion of the N-terminal helix would yield a 
fragment of 22.6 kDa.  The bands just below and just above the 25 kDa marker could 
therefore be the Ras-like domain of Gα13 including and excluding the N-terminal 
extension, respectively.  Because these bands are present even during lysis, it would 
indicate that Gα13 is partially digested during or even before lysis.  (6) Experiments to 
verify correctly folded and active Gα13 yielded negative results.  Activated Gα13 did not 
bind the LARG RH domain.  Trypsin protection assays did not show diminished 
digestion of AlF4- or GTPγS activated ∆N47Gα13 (Figure 2.9).   
 
Figure 2.8: Purification of the MBP-∆N47-Gα13 fusion protein shows an unidentified 
band just below 25 kDa.  MBP-∆N47-Gα13 was expressed in the E. coli strain HMS174 
(DE3) pLysS.  Cells were lysed with lysozyme, centrifuged, and the lysate was applied to 
a NiNTA column.  MBP-∆N47-Gα13 was eluted with 250 mM imidazole.  Samples of the 
various steps of the purification were subjected to SDS-PAGE and gels were stained with 




Figure 2.9:  Trypsin protection assay of MBP-∆N47-Gα13 fusion protein does not 
show protection of activated Gα13.  MBP-∆N47-Gα13 was incubated with either 30 µM 
AlF4- or 300 µM GTPγS and digests were performed with 0.01 % trypsin (w/w) at 37° C.  
At the indicated time points samples were subjected to SDS-PAGE and the gel was 
stained with Coomassie Brilliant Blue.  The identical pattern of digested bands under the 
different conditions indicates that the protein is not protected from trypsin digestion.  
 
Of the various attempts to express and purify functional Gα13 from E. coli the best 
purification of full length Gα13 could be achieved using 0.5% Thesit for lysis and NiNTA 
columns, and 10 mM CHAPS for the gel filtration column.  13 mg of MBP-Gα13 fusion 
protein could be retrieved per liter and, ultimately 100 µg of Gα13, which is equivalent to 
the yield from Sf9 insect cells as reported by Kozasa [68].  Probed with Gα13 and MBP 
antibodies it was shown clearly that the digested band contains both Gα13 and MBP, that 
MBP is filtered out by the NiNTA run, and that the eluate only contained Gα13 and MBP-
Gα13 fusion protein but no MBP (Figure 2.10).  Because MBP and Gα13 have the same 
molecular weight and cannot be distinquished on an SDS-PAGE gel, this was useful 
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information for the interpretation of peaks from gel filtration runs.  Strangely, although 
Gα13 is appended to an H6 tag, some Gα13 and MBP-Gα13 fusion protein could be 
detected in the flow through of the Ni-NTA column.  This could either indicate that the 
H6 tag was cut off, that the column was overloaded, or that some of the protein was 
aggregated in a way that prevented binding to the NiNTA resin.  Gα13 eluted from the gel 
filtration column in the void peak and in a peak at approximately 80 kDa, as probed with 
Gα13 antibody (Figure 2.7).  Although trypsin protection assays for this protein were 
performed, no reliable results were obtained.  The protein concentrations were too low to 
be visible on an SDS-PAGE gel stained with Coomassie Brilliant Blue.  Therefore, 
western blots had to be performed, which in this particular experiment gave inconclusive 
results.  However, trypsin digests have been performed on the MBP-∆N47-Gα13 fusion 
protein and did not show a different pattern of digested proteins between AlF4-, GTPγS, 
or GDP-bound Gα13 (see Figure 2.9).  It therefore was concluded that both, the MBP-
Gα13 fusion proteins and Gα13, retrieved from E. coli purifications are not functional, 
most likely because they are misfolded.  This is surprising especially for the MBP fusion 
proteins because they are expressed in a high yield as soluble proteins.  Although 
disappointing, this result is interesting, because it might indicate the potential of MBP as 
a chaperone, which can retain even misfolded protein in the soluble fraction during 
purification.  This might be useful for the purification of proteins that can be re-folded to 
a functional form.  In such cases expression of these proteins as MBP fusion proteins 




Figure 2.10:  Both, MBP and Gα13 are present in the TEV digest of MBP-Gα13-H6 
and can be separated by a NiNTA column.  Digested MBP-Gα13-H6 fusion protein was 
subjected to a NiNTA resin (Qiagen) and Gα13-H6 was eluted with buffer containing 
250 mM Imidazol.  Samples from various steps of the purification were subjected to 
SDS-PAGE.  Gels were transferred onto a nitrocellulose membrane and probed with anti-
MBP (New England Bioloabs) and anti-Gα13 (sc-140, Santa Cruz) antibodies.  MBP2 
(New England Biolabs) was used as a control for the specificity of the MBP antibody.  S: 
supernatant, D: digest, FT: flow through, E: eluate, MBP: MBP2 protein.  
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3.  The structures of the LARG DH/PH domains and their complex with RhoA  
 
3.1  Introduction 
Dbl family proteins 
RhoGEFs contain a Dbl homology (DH) domain that is responsible for nucleotide 
exchange on Rho GTPases and was first identified in the dbl oncogene product onco-Dbl, 
which was isolated from diffuse B-cell lymphoma cells [43].  Almost all RhoGEFs also 
contain a pleckstrin homology (PH) domain immediately C-terminal to the DH domain.  
Since the discovery of the oncoprotein Dbl, approximately 50 GEFs of the Dbl family 
have been identified by virtue of their transforming and metastasis inducing abilities [74].  
The Dbl family now represents the largest family of related oncoproteins.  The relevance 
of the Dbl family proteins in other pathologies is evidenced by several examples where 
RhoGEFs are found at the breakpoints of chromosomal rearrangements (e.g. LARG in 
MLL [52], FGD1 in Aarskog-Scott syndrome [75], bcr, Philadelphia translocation in 
CML and AML, [76]).  This may indicate an involvement of de-regulated RhoGEFs in 
the etiology of these diseases.  
 
Common structural features of DH/PH domains 
The DH and PH domains are around 250 and 100 amino acids long, respectively.  
From structural analysis of DH domains (β-PIX [8], Vav [7], Trio [9]), DH/PH domains 
(SOS [6]),  or DH/PH domains complexes with their respective GTPases (Dbs-Cdc42 [4], 
Dbs-RhoA, ITSN-Cdc42 [3], Tiam-Rac1 [5]) general structural features of the RhoGEF 
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DH and PH domains were defined.  The DH domain is an elongated bundle of six α 
helical segments (Fig. 3.15).  Within segments 1, 2, and 5 there are regions of high 
sequence conservation that have been termed the conserved regions one, two, and three 
(CR1, CR2, CR3), respectively.  CR1 and CR3 make direct interactions with the GTPase 
and harbor residues that are responsible for disruption of the magnesium binding site of 
RhoA.  CR2 contributes hydrophobic residues to a core that stabilizes the helical bundle.  
CR2 might also play a role in oligomerization of RhoGEFs, which is thought to be 
necessary for RhoGEFs to participate in several interconnected signaling pathways, 
where presumably large signaling complexes are formed.  Evidence for a role of the CR2 
in oligomerization comes from studies of Tiam and Dbl.  The CR2 of Tiam is involved in 
the dimer interface in the Tiam-Rac1 crystals [5].  However, the functional significance 
of dimerization in Tiam is unknown.  The CR2 of Dbl is required for its oligomerization, 
which is essential for Dbl-induced transformation [77].   
PH domains are comprised of an anti-parallel flattened β barrel that is capped on 
one end by a C-terminal α helix (Fig. 3.15, 3.18).  Unlike other PH domains, RhoGEF 
PH domains contain an N-terminal extension that is comprised of an α-helix, which is 
often an extension of the α6 segment of the DH domain, a β-strand (βN) and a 310 helix 
(310N).   
Although the common structural features in DH and PH domains have been 
identified, the details in the various DH/PH domains structures of individual RhoGEF 
family members have brought more insight into three major unresolved issues in 
RhoGEF research: (1) the specificity of the various RhoGEFs for their respective 
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GTPases, (2) the role of the PH domain in nucleotide exchange, and (3) the modes of 
regulation of RhoGEF activity.  A structure of the LARG DH/PH domains will expand 
knowledge in these areas and lead to a more complete understanding of signaling through 
RhoGEFs.  
 
Specificity of RhoGEFs 
RhoGEFs exhibit a wide range of specificities towards the various RhoGTPase 
subfamilies.  Some RhoGEFs are specific for one GTPase subfamily (e.g. LARG is 
specific for RhoA), others are more promiscuous and exchange on GTPases of two or all 
three subfamilies (e.g. Dbs exchanges on Cdc42 and RhoA, Vav exchanges on Cdc42, 
RhoA, and Rac1).  LARG belongs to the family of RH-RhoGEFs, that are RhoA specific 
and also include Lbc, Lfc, Net1, XPLN, PDZ-RhoGEF, p115RhoGEF and intersectin, 
and is called the Lbc RhoGEF family [45].  Intersectin is an outlier in this family because 
of its specificity for Cdc42 and not RhoA.  Understanding the molecular basis for the 
specificity of the various RhoGEFs will be helpful in designing inhibitors to specifically 
block signaling cascades of the various Rho GTPase subfamilies. 
The specificity determining regions in RhoGTPase and RhoGEFs have been 
studied by comparing structures of the RhoGEFs intersectin, Dbs, and Tiam with their 
respective GTPases .[3, 5].  These studies identified variant residues in the β2 and β3 
strands of Rho GTPases as the major specificity determining areas that are recognized by 
specific residues in the α5 helix of the RhoGEF DH.  The basis of the specific 
recognition of Rac1 by Tiam, Cdc42 by intersectin, and the recognition of both Cdc42 
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and RhoA by Dbs was at least partially explained [3, 5].  However, a DH/PH domain 
structure of a strictly RhoA-selective RhoGEF has not been available until now.   
 
Role of the PH domain in nucleotide exchange 
The conserved positioning of the PH domain immediately C-terminal to the DH 
domain in nearly all RhoGEFs suggests that it plays an important role.  PH domains are 
traditionally viewed as modules that recruit proteins to membranes and that can bind 
specific phospholipids [78, 79].  Recent evidence, especially from studies of RhoGEFs 
[80-83] and GRK2 [84], also points to a function of the PH domain as a protein 
interaction module for the recruitment to specific intracellular locations and for the 
docking of regulatory proteins or domains.  The Dbl PH domain has also been shown to 
associate with cytoskeletal proteins [79].  Furthermore, in the non-transforming Dbl 
protein proto-Dbl, which contains additional 500 amino acids N-terminal of the DH/PH 
module, compared to onco-Dbl, the N-terminus was shown to specifically bind to the PH 
domain [85].  This interaction is responsible for keeping Dbl in a non-transforming state.  
In Vav and SOS, the PH domains exert an inhibitory effect on the DH domain that is 
relieved upon PIP3 binding [86, 87].  The role of the PH domain in other RhoGEFs is less 
well understood.  The relative arrangement of PH to DH domains in RhoGEFs has been 
implicated in dictating the role of the PH domain in the exchange reaction.  The most 
divergent arrangement of the four known structures of DH/PH domains is seen in the 
SOS DH/PH domains [6].  However, the SOS DH/PH domains are different from the 
other DH/PH domains because of the inhibitory effect of the SOS PH domain on its DH 
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domain.  In fact, the SOS DH/PH domains are incapable of nucleotide exchange in vitro.  
The arrangement of the state that has been crystallized therefore likely represents the 
inhibited state of the DH domain.   
For three RhoGEFs (Dbs, Trio, and LARG) it has been shown that their DH/PH 
domains have higher catalytic activities than their DH domains alone [4, 9, 54] and 
therefore exhibit “PH domain-assisted nucleotide exchange”.  The mechanism of PH 
domain-assisted nucleotide exchange has only been explained for Dbs [4, 88].  In Dbs PH 
domain residues seem to support interactions of the α6 helical segment with the GTPase.  
However, the structures of RhoGEF PH domains, escpecially their loop regions, are 
variable and the structural basis for PH domain-assisted nucleotide exchange might vary 
among the different RhoGEFs.  
 
Regulation of RhoGEFs 
Intra-molecular regulation of the DH/PH domains by N- or C-terminal sequences 
seems to be a common theme in RhoGEFs.  Many RhoGEFs (e.g. proto-Dbl, proto-Lbc) 
have been discovered as a result of the isolation of their oncogenic N- or C-terminally 
truncated forms (e.g. onco-Dbl, onco-Lbc).  However, several other modes of inter- and 
intra-molecular regulation of the DH/PH module of RhoGEFs have been identified.  
Auto-inhibition of the DH domain by the PH domain and alleviation by PIP3 has been 
observed in SOS and Vav [86, 87].  Auto-inhibition by N-terminal regions, and release of 
the auto-inhibition by tyrosine phosphorylation has been reported for Vav [89] and a 
similar mechanism may also be regulating proto-Dbl activity [85].  Direct interaction of 
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regulatory proteins with the PH domain has been reported for Dbs, which seems to be 
regulated by interaction of Rac1 with the PH domain [40].  G protein βγ binding to the 
PH domain is also implicated in RhoGEF regulation [90].  The formation of homo- or 
hetero-oligomers has also been proposed as a means of RhoGEF regulation, especially 
when they participate in large signaling complexes.  There are examples of regulation of 
GEFs by oligomerization. Dbl forms oligomers through the CR2 in the DH domain, 
which, although not necessary for its in vitro exchange activity is necessary for its full 
catalytic activity in vivo [77].  The Tiam-Rac1 complex crystallized as a dimer 
(worthylake).  The dimer interface includes an extensive hydrophobic surface area in the 
CR2, which also points to the possibility that tiam is regulated by oligomerization.  
Although there are no reports on regulation of the RH-RhoGEF PH domain by 
phospholipids or inhibition of the DH domain by the PH domain, auto-inhibition by N-
terminal sequences has been implicated in the regulation of p115RhoGEF.  It has been 
shown that deletion of the N-terminal region of p115RhoGEF, including the RH domain 
enhanced GEF activity on unprenylated RhoA [56].  For LARG it has been shown that if 
the RH domain is overexpressed signaling to the serum response element (SRE) is 
diminished [91].  This might indicate that the RH domain associates with and regulates 
the DH/PH domains.  However, it is unknown which regions in the DH/PH domains 
associate with the RH domain.  
Direct association of the DH/PH domains with Gα13 has also been proposed as a 
mode of regulation for the RH-RhoGEFs.  Studies with p115RhoGEF identified a C-
terminal region including the DH/PH domains as an association site for Gα13 [58].   
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Structural analysis of the LARG DH/PH domains will aid in identifying intra-
molecular interaction sites for the RH domain and inter-molecular interaction sites for 




The objectives of the present study were to determine the structure of the LARG 
DH/PH domains and their complex with RhoA and to answer three questions about the 
molecular biology of LARG:  (1) What is the structural basis of the specificity for the 
RhoA subfamily?  (2) What is the structural basis for PH domain-assisted nucleotide 
exchange in LARG?  (3) Can the structures reveal possible modes of regulation of the 
DH/PH domains, in particular possible docking sites for Gα13 or the RH domain?  
 
Described in the following section are the cloning, expression and purification of 
the LARG DH/PH domains and its substrate RhoA and crystallization and structure 
determination of the DH/PH domains and the DH/PH-RhoA complex. 
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3.2  Methods 
3.2.1  Cloning, Expression and Purification of the LARG DH/PH domains  
A fragment of human LARG encoding the DH/PH domains (residues 765 to 
1138) was amplified from the pcDNAmycI-Full382 vector (a gift from Dr. T. Kozasa).  
This vector encodes the LARG gene KIAA0382 (accession number 2224704), which has 
a single nucleotide polymorphism (SNP) in the DH/PH sequence compared to the other 
LARG gene in the NCBI data base, ARHGEF12 (accession number 34395525).  This 
SNP results in the translation of residue 973 as phenylalanine instead of tyrosine.  The 
amplified DH/PH fragment was inserted into a modified pMALc2X vector (New England 
Biolabs) using BamH I and Sal I restriction sites (Figure 3.1.) [92].  This modified vector 
(pMALc2TBamHI_H6) was generated by replacing the factor Xa protease cleavage site 
with that of tobacco etch virus (TEV) protease, and inserting a sequence that encodes for 
a C-terminal hexahistidine (H6) tag followed by a stop codon.  The pMALc2X vector was 
first digested with restriction enzymes Ava I and BamH I.  5' phosphorylated 
oligonucleotides encoding the TEV protease cleavage site (tcggggaaaacctgtattttccagg and 
gatccctgaaaatacaggttttcc, Integrated DNA Technologies) were mixed in equimolar 
amounts, heated to 80 ºC for 10 min, allowed to cool and ligated with the digested 
pMALc2X vector using T4 DNA ligase (Sigma).  To insert the sequence for the C-
terminal H6 tag, the vector was then digested with the restriction enzymes Sal I and Hind 
III, and complementary oligonucleotides (tcgacggaggtcaccaccaccaccaccactaaa and 
agcttttagaggaggaggaggaggagacctccg,, Integrated DNA Technologies) were inserted as 
described above.  In the process of cloning the LARG DH/PH domains a silent mutation 
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was introduced at residue Asp765.  The LARG DH/PH fragment, expressed from the 
pMALc2TBamHI_LARG-DHPH_H6 vector is a fusion protein with maltose binding 
protein (MBP) at the N-terminus and a H6 tag at the C-terminus.  After treatment with 
TEV protease, the H6-tagged DH/PH domains have a molecular weight of approximately 
43 kDa. 
 
Figure 3.1:  Vector map of the expression vector for the LARG DH/PH domains, 
pMALc2TBamHI_LARG-DHPH_H6.  The LARG DH/PH domains were expressed as N-
terminal fusion protein with maltose binding protein (MBP) and a C-terminal H6 tag.  
After cleavage with TEV protease the DH/PH domains contain additional two amino 
acids at the N-terminus and four amino acids followed by an H6 tag at the C-terminus.  
Arrows indicate the start of the coding regions for the Ptac promotor (Ptac), lac repressor 
(lacIq), β-lactamase (AmpicillinR), and maltose binding protein (malE). 
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The DH/PH fragment of LARG was expressed and purified as described for the 
LARG RH domain in 2.2.1 and in [92], except that the MBP-DH/PH fusion protein was 
digested with 1.5% (w/w) TEV protease (Fig 3.2).  The LARG DH/PH domains eluted 
from the gel filtration column with an apparent MW of 33 kDa (Fig. 3.3), and 
subsequently were concentrated to approximately 10 mg/ml and stored at -80 ºC.  The 
typical yield was 15 mg protein per liter of cell culture. 
 
Figure 3.2:  Purification of the MBP-DHPH fusion protein and the DHPH 
domains on Ni-NTA columns.  The MBP-DHPH fusion protein was overexpressed in 
Rosetta (DE3) pLysS cells.  Cells were lysed with lysozyme in the presence of protease 
inhibitors.  The cell lysate was applied to a NiNTA column (left panel), the column was 
washed with 10 column volumes of buffer and the MBP-DHPH fusion protein was eluted 
with buffer containing 250 mM imidazole.  Subsequently, the eluate was dialyzed against 
buffer without imidazole and in the presence of 1.5 % TEV protease.  The digest, which 
contained MBP (43 kDa) and the DHPH domains (43 kDa), was applied to a second 
NiNTA column (right panel).  The flow through from this column contained MBP and 
the DHPH domains were eluted as described above.  S: supernatant, P: pellet, F: flow 
through, W1: wash with lysis buffer, W2: wash with buffer containing 10 mM imidazole, 
E: eluate, D: digest.  
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Figure 3.3:  Gel filtration of the LARG DH/PH domains.  The eluate from the nickel 
affinity column (NiNTA-2, Fig. 3.2) was concentrated and loaded on a gel filtration 
column (S200 16/60, Amersham Pharmacia) pre-equilibrated with gel filtration buffer 
(20 mM HEPES pH 8.0, 10 mM NaCl, 1 mM DTT).  The LARG DH/PH domains eluted 
at a flow rate of 0.75 ml/min and with an apparent MW of 33 kDa.  Fractions 36 to 48 
were pooled.  
 
TEV protease was expressed from the pRK793 expression vector (a gift from Dr. 
D. Waugh [93] in the E.coli expression strain BL21-RIL (Novagen).  Protein expression 
was induced with 1 mM IPTG and cells were grown at 30° C for 4 hours.  Lysis was 
performed as described above for the DH/PH domains, using TEV-lysis buffer (20 mM 
HEPES pH 8.0, 100 mM NaCl, 25 mM imidazole pH 8.0, 10 mM βME, 10% glycerol).  
The lysate was loaded onto a Ni-NTA column (Qiagen) that was pre-equilibrated with 
TEV-lysis buffer.  The column was then washed with 10 column volumes of TEV-lysis 
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buffer, and TEV protease was eluted in 1 ml fractions with TEV-elution buffer (TEV-
lysis buffer with 250 mM imidazole pH 8.0).  Fractions containing TEV protease were 
pooled, concentrated to less than 1 mg/ml, and loaded onto a size exclusion 
chromatography column (S200 16/60, Amersham Pharmacia Biotech), which was pre-
equilibrated with TEV-gel filtration buffer (20 mM HEPES pH 8.0, 200 mM NaCl, 2 mM 
EDTA, 10 mM DTT, 10% glycerol).  Fractions containing TEV protease were pooled, 
concentrated to approximately 1 mg/ml and stored at -80 ºC. 
 
3.2.2 Crystallization of the LARG DH/PH domains  
Initial crystal clusters (Fig 3.4.a) were obtained by the hanging drop vapor 
diffusion method at 4 ºC from drops containing 1 µl of the concentrated protein (10 
mg/ml) and 1 µl of a well solution (15 % PEG 3350, 1 M NaCl and 100 mM sodium 
citrate pH 6.5) suspended over 1 ml of the well solution.  Upon refinement of 
crystallization conditions, single crystals (Fig. 3.4.b.) were grown at 4 ºC in 8 to 11 % 
PEG 3350, 0.8 to 1.1 M NaCl and 100 mM sodium citrate pH 6.5.  Nucleation occurs 
within three days and crystals reach their maximum size in about two weeks.  Crystals 
belong to spacegroup C2 and have unit cell dimensions of a = 195.5 Å, b = 46.0 Å, c = 
75.1 Å and β = 105.0º.  The Matthews coefficient (VM) indicated that there are either 1 or 
2 monomers per asymmetric unit (VM  = 3.5 Å3 Da-1 and 1.8 Å3Da-1), corresponding to a 
solvent content of 65 and 31 %, respectively.  Structure determination later revealed that 
the crystals contained only 1 monomer per asymmetric unit.  The crystals must be 
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harvested within several weeks of growth to avoid gradually increasing mosaicity and 
loss of resolution. 
 
Figure 3.4:  Crystals of the DH/PH domains of human Leukemia-associated 
RhoGEF (LARG).  (a) Initial crystals grown as needle clusters (approximate dimensions 
0.2 x 0.02 x 0.02 mm).  (b) Single crystals grown under optimized conditions.  (c) A 
single crystal grown under optimized conditions (approximate dimensions 0.4 x 0.2 x 
0.05 mm). 
 
3.2.3   Harvesting of LARG DH/PH crystals 
Crystals were harvested by gradually adding 1 µl cryoprotectant solution at a time 
to the hanging drop and subsequently transferring crystals to the cyroprotectant solution 
using cryoloops (Hampton Research).  The cryoprotectant solution for the DH/PH 
domains crystals contained: 15 % ethylene glycol, 20 % PEG3350, 0.6-1 M sodium 
chloride, 100 mM sodium citrate pH 6.5, 20 mM HEPES pH 8.0, and 2 mM DTT.  
 
3.2.4   Data collection and processing for LARG DH/PH crystals 
Native data sets of the DH/PH domains crystal were collected on a MAR345 
imaging plate detector using Cu Kα radiation from a Rigaku RU-200H rotating anode 
51 
(dhph15, diffraction to 2.5 Å spacings), as well as on a Quantum 4 CCD detector (ADSC) 
using x-rays from a synchrotron source at BIOCARS beamline 14D at the Advanced 
Photon Source (APS) (dhph30, dhph45, diffraction to 2.07 and 2.0 Å spacings, 
respectively) (Tables 3.1 and 3.6).  The temperature was maintained at 95 K and 90 K, 
respectively, with an Oxford Instruments Cryojet.  Data sets collected at the APS were 
used for structure determination and refinement.  Data sets of sodium bromide (dhph65) 
and xenon (dhph63) derivatives of the DH/PH crystals were collected using CuKα 
radiation on a MAR345 imaging-plate detector.  The temperature was maintained at 95 K 
with an Oxford Instruments Cryojet.   
Data were reduced and scaled using the HKL2000 package [94]. A sigma cut off 
of -1 was applied.  The mosaicity of the diffraction pattern was 0.3.  
 
 
Table 3.1: Data collection statistics of crystals used for the structure determination 
of the LARG DH/PH domains.   
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Table 3.2: Scaling statistics for the dhph30 crystals.  Reflections were integrated with 
the program DENZO and scaled with the program SCALEPACK.  
 
3.2.5  Structure determination of the LARG DH/PH domains 
Molecular replacement is a method for the determination of phases that requires a 
homologous protein of known structure with approximately 30% sequence identity and 
structural homology to the protein under scrutiny.  Molecular replacement for the phase 
determination of the LARG DH/PH domains seemed to be the logical first approach for 
their structure determination because three structures of homologous DH/PH domains 
(Tiam, Dbs, intersectin) are available and have 23, 25, and 29% sequence identity to the 
LARG DH/PH domains, respectively.  In molecular replacement, a Patterson map of the 
search model is generated and rotated to fit the Patterson map of the protein under 
scrutiny.  The Patterson function describes the distances between atoms and can be 
generated without any phase information.  Once the orientation of the model is fixed, a 
translation function is performed, where the search model is moved through the 
asymmetric unit and structure factors are calculated and compared to the observed 
structure factors.  Peaks from the rotation and translation functions are recorded and 
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scored.  Structure factors can then be generated for the various solutions and, if correct, 
the resulting phase information can be used to generate initial electron density maps.  
The programs MOLREP [95] and EPMR [96] were used and search models were 
generated from the Tiam, Dbs and intersectin DH/PH domains (PDB codes: 1FOE, 
1LB1, 1KI1, respectively).  Search models from only the DH domains of these proteins 
were also used, because the respective PH domains of these proteins assume very 
different positions relative to the DH domains and it is likely that this is also the case for 
the LARG DH/PH domains.  MR with the DH/PH domains would therefore increase the 
structural divergence to the search model and decrease the likelihood of finding a correct 
MR solution.  Furthermore, a homology model of LARG, that was based on the closest 
LARG homolog intersectin, was used as a search model.  The homology model was 
generated with the Swiss pdb-viewer program SWISS-MODEL [97], using intersectin as 
a template.  Poly-alanine models of these DH domains were also generated with the 
program MOLMAN [98].  The CCP4 suite program MOLREP [95] was used with the 
option of consideration of the anisotropy of the diffraction pattern.  The validity of the 
molecular replacement solutions was investigated by analyzing crystal packing using the 
program O [99].  Most molecular replacement solutions had high R factors and low 
correlation coefficients (Table 3.6) and showed impossible crystal packing, where the DH 
domains were lined up in sheets and the gaps between sheets were too big to be gapped 
by the PH domain.  Although no convincing translation function solution was found, a 
recurring rotation function solution was observed when the DH and DH/PH domains of 
intersectin and the homology model, based on intersectin were used as search models 
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(Table 3.6).  This rotation function solution was later used for the improvement of 
MIRAS-phased electron density maps (see later section), by translation into density and 
phase combination with MIRAS-derived phases.  Because of the failure of structure 
determination by MR alone, the two other methods for phase determination, multiple 
anomalous diffraction (MAD) and multiple isomorphous replacement (MIR), were 
explored.   
 
Multi-wavelength anomalous diffraction (MAD) 
 MAD takes advantage of the fact that atoms can absorb x-rays at characteristic 
wavelengths, which results in changes of the real and an imaginary components of the 
scattering factor.  Diffraction patterns are therefore collected at multiple wavelengths 
around the absorption edge of the anomalous scatterer to alter the observed structure 
factor amplitude, and tunable synchrotron radiation is required.  Anomalous diffraction 
can be gained from heavy metal atom derivatives or from proteins that have 
selenomethionine incorporated instead of methionine, because these elements have 
accessible absorption edges.  The LARG DH/PH domains contain 6 methionines, which 
would allow a MAD structure determination.  
Production of Selenomethionine substituted LARG DH/PH domains 
 A protocol for the incorporation of selenomethionine into recombinant protein by 
LeMaster was followed [100].  The methionine auxotroph E. coli strain B384 (DE3) 
pLysS was used as the expression strain for the LARG DH/PH domains.  A starter culture 
of 50 ml LB media was inoculated, incubated overnight and expanded to 1 liter of 
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LeMaster selenomethionine medium, which contains glucose, 17 amino acids, the bases 
for nucleic acids, various salts, sulfate, and 50 mg selenomethionine per liter of medium.  
The culture was grown to OD600 = 0.6 and harvested and purified as described for the 
native LARG DH/PH domains (3.2.1).  
Although selenomethionine-incorporated LARG DH/PH domains were 
successfully produced and crystallized in the form of needle clusters, refinement of the 
crystallization conditions did not result in well diffracting crystals.  Only long, thin 
needles (approximate dimensions: 0.2 x 0.02 x 0.02 mm) could be harvested from the 
needle clusters, and they showed only weak diffraction.  Furhtermore, these clusters did 
not exhibit the characteristic selenium absorption edge in a fluorescence scan at the 
synchrotron.  
 
Multiple isomorphous replacement with anomalous scattering (MIRAS) 
The structure of the LARG DH/PH domains was finally determined by a 
combination of multiple isomorphous replacement with anomalous scattering (MIRAS) 
and molecular replacement (MR).  Multiple isomorphous replacement requires the 
derivatization of the protein crystals by a strong scatterer, preferably a heavy metal 
compound.  The positions of the heavy metal atoms can be determined by inspection of a 
difference Patterson map.  Difference Patterson maps are generated by a Fourier 
synthesis with the phaseless quantitiy |F|2 (structure factor squared) as the coefficient 
instead of F.  Peaks in the Patterson maps are distance vectors between atoms.  Peaks 
corresponging to difference vectors between symmetry related heavy atoms are 
56 
accumulated at special sections, called the Harker sections.  Cross peaks between heavy 
atoms can be found on non-Harker sections.  When two heavy atom positions have the 
same y-coordinate, in spacegroup C2, their cross peaks are also found on Harker sections.  
Once the coordinates of the Patterson peaks are known the heavy metal positions in the 
unit cell and their phase angle (αH) and structure factors (FH) can be determined.  The 
protein phase angles (αP) are then derived from the structure factors of the protein (FP) 
which can be derived from FP = FPH-FH.  The phase information can then be used to 
generate an electron density map.  
Derivatization of the DH/PH domains crystals was initially attempted with several 
platinum and mercury compounds by soaking the crystals in solutions of these 
compounds at varying concentrations for varying times.  Soaking in thimerosal at 
0.5 mM for 1 hr lead to cracks in the crystals.  Soaks in 0.5 mM K2PtCl4, platinum 
pyridinium chloride, and mercury fluorescein preserved isomorphism and diffraction (to 
2.5 Å and 3.2 Å, respectively) but did not result in useful derivatives as determined by 
scaling with HKL2000 [94] or inspecting difference density maps. 
Many heavy atom compounds have useful anomalous signals at the CuKα 
wavelength and anomalous scattering can be included in isomorphous phasing. 
A xenon derivative was generated by subjecting a crystal to 520 psi xenon in a xenon 
chamber (Hampton Research) for 30 min at 4 ˚C.  A bromide derivative was generated by 
soaking crystals in cryoprotectant solution, with NaBr substituting for NaCl, for 48 hours.  
Data collection and processing was done as described above for the native DH/PH 
domains, except that a full 360º of data was collected.  This is to ensure all Bijovet pairs 
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are collected ata reasonably high redundancy.  Collecting as many degrees as possible 
improves the statistics.   The xenon and NaBr derivatives were assessed for their potential 
as isomorphous derivatives by scaling derivative and native data sets together using the 
program SCALEPACK of the HKL package [94].  Two parameters in the scaling output 
file, χ2 and Rsym, give information about the isomorphism of the two crystals and the 
quality of the derivative.  χ2 is a measure of the error associated with fitting an observed 
reflection to a predicted reflection and should have a value of 1-2 if the sigmas of I 
(intensities) are estimated correctly.   If a native data set and that of a derivative are 
scaled together, χ2 will ideally have values of around 10 or higher.  If χ2 is ~1 no useful 
derivative is present.  If χ2 is very large (~50) the derivative crystal is probably non-
isomorphous.  The second parameter in the scaling output file that can give information 
about the presence of a derivative is Rmerge, which is Rsym of the merged data sets.  Rsym is 
a measure of the errors within a data set and more specifically of the agreement of the 
intensities of symmetry related reflections.  Two independent data sets will have a 
theoretical Rmerge of 0.57.  Rsym typically increases with increasing resolution, because 
high resolution data cannot be measured accurately.  When a derivative and native data 
set are scaled together and they are isomorphous, the Rmerge distribution with increased 
resolution will ideally be flat.  An increasing distribution is indicative of non-
isomorphous crystals.  The xenon and sodim bromide derivatives had a higher degree of 
isomorphism with different native datasets (dhph45 and dhph30, respectively; see Table 
3.1).  Because, the phasing statistics for the xenon derivative were better, the dhph45 data 
set was used for MIRAS phasing (Table 3.1).  However, the other native data set 
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(dhph30) was used for refinement, because it was more complete (98.3 % for dhph30 
versus 96.8 % for dhph45).  
After evaluation of the derivatives by scaling in SCALEPACK (Tables 3.3 and 
3.4), derivative and native data sets were merged using the program CAD from the CCP4 
program suite [101] and scaled together with the program SCALEIT [101].  
Subsequently, isomorphous and anomalous difference Patterson maps were generated.  
The xenon derivative generated interpretable isomorphous and anomalous difference 
Patterson maps. 
Three prominent peaks were seen on the Harker sections as well as one prominent 
peak on a section other than the Harker section (Figure 3.5).  The same peak pattern was 
observed in isomorphous and anomalous difference Patterson maps (Figure 3.7).  One of 
the prominent peaks and a weaker peak on the Harker section were identified as xenon 
site 2 (Xe2) and xenon site 1 (Xe1).  The other two prominent peaks were identified as 
cross peaks of two sets of symmetry related Xe1 and Xe 2.  Both cross peaks occur on the 
Harker section because Xe1 and Xe2 have the same y coordinates.  The two peaks on the 
Harker section were refined using the program MLPHARE [102].  A third xenon site (Xe 
3) was identified with the help of difference Fourier maps and the cross peaks on section 




Table 3.3: Scaling statistics for the combined scaling of native (dhph45) and xenon 
derivative (dhph63) data sets.  Reflections were integrated with the program DENZO 




Table 3.4: Scaling statistics for the combined scaling of native (dhph45) and NaBr 
derivative (dhph65) data sets.  Reflections were integrated with the program DENZO 





Figure 3.5:  Patterson maps of the xenon derivative of the LARG DH/PH domains. 
Four unit cells of the Harker section (v = 0) and section v = 0.12 of the isomorphous 
difference Patterson map are shown, contoured starting at 2.0 σ in steps of 4.0 σ for the 
Harker section and in steps of 2.0 σ for the section v = 0.12.  Xenon peaks and cross 




Figure 3.6: Isomorphous and anomalous difference Patterson maps show the same 
peaks.  One unit cell of the Harker section (v = 0) of isomorphous and anomalous 
difference Patterson maps of the DH/PH xenon derivative contoured starting at 1.0 σ in 
steps of 1.0 σ are shown.  
 
The NaBr derivative had only one site, which was identified in difference Fourier 
maps generated using the xenon-derived phases.  The statistics for the xenon and bromide 
site refinement are shown in Table 3.5.  Although, the phasing power for the sodium 
bromide derivative is unusually low, refinement statistics (i.e. lack of closure, figure of 
merit) for the bromide site in MLPHARE indicated that this derivative contributed to the 
phase information.  To further investigate the contribution of the individual derivatives to 
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the phase, a plot of the cosine of the phase differences against resolution was generated 
for the xenon and sodium bromide derivatives (Figure 3.7).  This plot shows that the 
anomalous phase information of the xenon derivative and the phase information of the 
bromide derivative only contributed to the correct phases at high resolution (>3.8 Å for 
the xenon anomalous phases and >3.1 Å for the bromide isomorphous phases).  
 
Figure 3.7: The anomalous signal of the xenon derivative and the isomorphous 
signal of the bromide derivative contribute to the phase information only at high 
resolution.  The resolution-dependent mean phase discrepancies for the xenon and 







Figure 3.8: Flow chart of the steps involved in the phase determination of the LARG 
DH/PH domains by a combination of MIRAS and MR.   
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Molecular Replacement (MR) 
Inspection of the MIRAS-phased electron density maps in the program O [99] 
made it possible to manually place a molecular replacement solution of a homology 
model of the LARG DH domain (see 3.2.9).  The molecular replacement solution was 
generated with the program MOLREP of the CCP4 suite [95] and had a peak height 
(RF/σ) of 6.51.  The manual placement of the molecular replacement solution only 
involved translation and not rotation.  Phases of the manually placed molecular 
replacement solution were calculated with the program SFALL [101] and combined with 
MIRAS-derived phases from the MLPHARE output using the program SIGMAA [101] 
(see Fig. 3.8).  After phase combination the electron density improved considerably and 
the resulting electron density maps allowed placement of a homology model of the 
LARG PH domain.  The quality of the electron density further improved after phase 
combination of the PH and DH domains and density modification with the program 
SOLOMON from the CCP4 suite [101].  Model building in O [99] was then alternated 
initially with refinement in CNS [103] and subsequently in REFMAC including TLS 
refinement (see 3.2.11).  However, electron density remained ambiguous for the N-
terminus of the DH domain (residues 765-770), the N-terminus of the PH domain (999-
1008), the β1-β2 loop (1029-1035), the insert in the β4 strand (1062-1073), the β5-β6 
loop (1094, 1095), and the C-terminus of the PH domain (1136-1138) (Figure 3.15).  
Model building was further assisted by the structure of the DH/PH-RhoA complex (see 
next section), which facilitated interpretation of these regions and the final structure of 
the DH/PH domains lacks one residue at the N-terminus (residue 765) of the DH domain 
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as well as seven residues within the βN-N3/10 loop (residues 1000-1006), 13 residues 
(residues 1062-1074) within the β4 strand (1062-1074), and one residue (residue 1093) 
within the β5/β6 loop of the PH domain.  Ninetytwo water molecules were included in 
the structure and only assigned to the DH domain.  The PH domain has considerably 
higher B-factors and no obvious water molecules were evident in the electron density 
maps.  The criteria used for the water molecules were: (1) the peak in the electron density 
map is at least 3σ, (2) the water molecule is involved in at least two hydrogen bonds, and 
(3) the hydrogen bond distance does not exceed 3.5 Å.   
 
3.2.6  Refinement of the LARG DH/PH structure 
Initial simulated annealing and individual B-factor refinement was performed in 
CNS [103] followed by refinement with the program REFMAC [101] with TLS 
refinement [104].  TLS refinement is a method that takes into account the displacement 
of atoms due to anisotropy of the data.  In TLS refinement it is assumed that the 
displacement of neighboring atoms is correlated.  Therefore pseudo-rigid bodies are 
defined (TLS groups), for which refinement parameters are selected, that describe the 
translation, libration, and screw-rotation of the pseudo-rigid bodies.  The LARG DH 
domain and the PH domain were considered as separate TLS groups.  Waters were only 
assigned to the DH domain and therefore grouped with the DH domain.  The structure 

















MR phasing and 
refinement 
Wavelength (Å) 1.0 0.9794 1.5418 1.5418 1.0688 
Spacegroup C2 C2 C2 C2 C2 
Unit cell (Å, º) a = 193.6 a = 195.5 a = 194.4 a = 194.1 a = 294.91 
 b = 45.9 b = 46.0 b = 46.1 b = 45.9 b = 95.0 
 c = 74.7 c = 75.13 c = 75.0 c = 74.8 c = 157.03 
 β = 107.5 β = 105.0 β = 104.5 β = 106.6 β = 94.04 
Resolution (Å) 2.13 2.05 3.5 2.4 3.2 
Unique reflections (total) 35477 (814907) 41093 (518961) 8384 
(67240) 
25235 (120925) 70549 (1360421) 
Completeness (%)† 98.3 (93.7) 96.8 (97.8) 100 (100) 99.8 (100) 91.2 (57.4) 
Rsym (%) § 4.6 (36.5) 4.8 (51.4) 7.9 (16.1) 6.2 (42.3) 8.3 (57.4) 
Average I/σ(I) 21.0 (3.3) 24.0 (3.1) 28.6 (12.6) 32.2 (4.8) 11.4 (1.4) 
Phasing power‡ 
         Cenctric 
















Resolution range for 
refinement (Å) 
 








158.11 to 3.19 
Total reflections used 35784 - - - 61716 
Number of protein atoms 2880 - - - 16906 












RMSD bond lengths (Å) 0.014 - - - 0.04 
RMSD bond angles (°)  1.31 - - - 2.91 
Rwork|| (%) 23.8 - - - 25.6 
Rfree¶ (%) 28.2 - - - 30.6 
Average B-factor (Å2) 34.9 - - - 45.0 
†Values in parentheses refer to the highest resolution shell (DH/PH: 2.12-2.05 Å, DH/PH-RhoA: 3.31-3.2 Å). 
§Rsym = Σ |I-Iavg|/ΣI, where the summation is over all symmetry-equivalent reflections, excluding reflections observed 
only once. 
|| Rwork = ∑h ||Fobs(h)|-|Fcalc(h)|| / ∑h|Fobs(h)|; no I/σ cutoff was used during refinement. 
¶ 5% of reflections were reserved from refinement for the calculation of Rfree.  
‡ Phasing power = (FH/LOC), where LOC is the lack of closure. 
Table 3.5:  Data collection, phasing and refinement statistics for the LARG DH/PH 




Two residues in the DH/PH domains, Ser833 and Asp1054, fall within the 
disallowed region of the Ramachandran plot.  In other atomic structures of DH domains, 
residues equivalent to Ser833 have the same strained backbone stereochemistry suggesting 
its conformation is required to maintain the DH domain fold.  Ser833 in the LARG DH 
domain seems to be distorted because the adjacent Phe832, which is highly conserved in 
RhoGEF DH domains, participates in a conserved hydrophobic core that holds together 
helices α1, α3, α4, and α5.  Thus, the DH domain can energetically afford to keep a 
residue with disallowed stereochemistry because it gains binding energy through 
interactions in the hydrophobic core.  Asp1054 exists in the i+1 position of a type I β-turn 
in the PH domain (β3-β4 loop), which in most turns is normally occupied by glycine. 
 
3.2.7  Analysis of crystal packing in the DH/PH crystals  
Analysis of the packing of DH/PH molecules reveals a hydrophobic patch on the 
PH domain that could potentially be involved in protein-protein interactions and 
exploited for regulation of the DH/PH domains.  PH domains in the DH/PH domains 
crystals interact via a hydrophobic interface formed by the β4-β7 sheet, involving 
exposed aromatic and aliphatic residues (Leu1086, Phe1098, Ile1109, Ile1100, Ala1107).  
Interestingly, the same site on the PH domain is involved in crystal contacts of the 
DH/PH-RhoA complex, further confirming that this hydrophobic patch is a potential 
protein-docking site (see 3.3.10).  
68 
Analysis of the crystal packing of the DH/PH domains crystals also explains the 
high degree of anisotropy in these crystals.  The diffraction pattern showed good 
diffraction along the z-axis of the crystals and poor diffraction along the x-axis of the 
crystals.  This is a result of alignment of the DH domains in sheets that run parallel to the 
y-z plane, and connection of the sheets by the highly mobile PH domains that align 
parallel to the x-axis.  This formation leaves the crystal lattice with channels that measure 
about 70 x 60 Å in the x and z directions, respectively. 
 
Figure 3.9: Crystal packing of the LARG DH/PH domains in spacegroup C2, 
looking down the y-axis.  The DH and PH domains are rendered as orange and blue 
tubes, respectively.  One unit cell is shown as a green box.  DH domains aligned in sheets 
that run parallel to the yz plane.  PH domains align parallel to the xy plane.  The crystal 
packing explains the good diffraction along the z-axis but poor diffraction along the x-
axis.     
69 
3.2.8  Analysis of the failure of molecular replacement 
 Molecular replacement for the phase determination of the LARG DH/PH domains 
seemed to be the logical first approach for their structure determination since three 
structures of homologous DH/PH domains (Tiam, Dbs, Intersectin) are available and 
have 23, 25, and 29% sequence identity to the LARG DH/PH domain, respectively.  
However, solving the phase solely by molecular replacement was not possible with the 
progams MOLREP [95] and EPMR [96].  This is not surprising if the DH/PH domains 
are used as a search model, because the relative disposition of DH to PH domain is highly 
divergent in RhoGEFs (Fig. 3.19).  However, RhoGEF DH domains are structurally fairly 
homologous and it was therefore surprising that even when the DH domain by itself was 
used as a search model it did not yield the correct molecular replacement solution.  The 
CCP4 suite program MOLREP [101] was run with the option of consideration of the 
anisotropy of the diffraction pattern and it resulted in a recurring rotation function 
solution when intersectin and the homology model were used as search models (Table 
3.6).  However, no convincing translation function peaks were found.  The best molecular 
replacement solutions were visualized in the unit cell using the program O [99].  But the 
packing of the DH domain usually showed overlaps or the distances between DH 
domains were to big to be gapped by PH domains and the solutions would therefore not 
be consistent with a protein lattice.  Since the DH domains of RhoGEFs whose structures 
have been previously determined (Tiam, Intersectin, Dbs, Vav, β-PIX, Trio) are all 
structurally very similar and PH domains also share close structural homology it was 
concluded that one reason for the failure of the molecular replacement programs to pick a 
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convincing solutions was likely the arrangement of the PH domain relative to the DH 
domain.  Indeed the realtive arrangement of the LARG DH and PH domains is different 
from that of intersectin.  Although the arrangement in LARG is similar to that of Dbs, 
Dbs was also not a good search model, possibly due to a 13 Å translation of the PH 
domain along the α6 segment of the Dbs DH domain.   
 In an attempt to analyze the failure of molecular replacement, the solved structure 
of the DH/PH domains was used to search for a MR solution with intersectin or the 
homology model, based on intersectin as the search models (Table 3.6).  However, 
inspection of the best solutions in the program O revealed that MOLREP could not pick 
the correct packing of the DH domains within the layers of DH domains that are present 
in the crystals (see Fig. 3.9).  
 
 
Table 3.6:  Molecular replacement (MR) using the final model of the LARG DH and 
DH/PH domains as a search model, in comparison with MR solutions using the DH 
and DH/PH domains of a homology model and intersectin as the search models.  The 
CCP4 program molrep picked a recurring rotation function solution.  Although some 
translation function peaks of intersectin and the homology model seem to be equivalent 
to the peaks of the final model, the fractional coordinates cannot be directly compared 
because MOLREP moves each model to its center of mass, which is different for each 
model.  However, inspection of the solutions in the program O revealed that the molrep 
solutions occupied the same space as the final model in the unit cell but that MOLREP 
could not pick the correct packing of the DH domains within the layers of DH domains 
that are present in the crystals (see Fig. 3.9).  
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3.2.9   Expression and Purification of RhoA in E.coli from pGEX-KG-RhoA 
Human RhoA (residues 1-193) was expressed from the pGEX-KG-RhoA vector 
(a gift from Dr. T. Kozasa) as an N-terminal fusion protein with glutatione-S-transferase 
(GST) containing a thrombin cleavage site.  Rosetta (DE3) pLysS cells (Novagen), 
harboring the pGEX-KG-RhoA plasmid were grown to OD600 = 0.6, induced with 1 mM 
IPTG at 30 °C and harvested after 5 hrs by centrifugation at 3500 rpm in a Beckman 
Coulter Avanti J-20 centrifuge, using a JLA 8.100 rotor.  The cell pellet was frozen in 
liquid nitrogen and stored at -80 ºC until purification.  
Cells were lysed with lysozyme (Sigma) (1 mg/ml) in lysis buffer 
(20  mM HEPES pH 8.0, 150 mM NaCl, 10 % Glycerol, 5 mM DTT, 50 µM GDP) in the 
presence of 0.3 mM EDTA and protease inhibitors (1 µM leupeptin, 1 mM lima bean 
trypsin inhibitor, 1 mM PMSF, and 1 mM TPCK).  Lysates were supplemented with 
10 mM MgCl2 and 20 µg DNaseI (Sigma) per gram of E.coli and centrifuged for 45 min 
at 35000 rpm in a Beckman Coulter Optima LE-80K ultracentrifuge, using a Type 45 Ti 
rotor.  The supernatant was loaded onto a drip column containing glutathione-
sepharose 4B (Amersham Pharmacia Biotech Inc), which was pre-equilibrated with 
equilibration buffer (20  mM HEPES pH 8.0, 150 mM NaCl, 10 mM MgCl2, 
10 % glycerol, 1 mM DTT, 50 µM GDP).  After washing with 10 column volumes of 
equilibration buffer, protein was eluted in 1 ml fractions in equilibration buffer 
supplemented with 10 mM glutathione.  Fractions containing the GST-RhoA fusion 
protein were pooled and dialysed overnight against dialysis buffer (20 mM HEPES pH 
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8.0, 150 mM NaCl, 10 mM  MgCl2, 10 % glycerol, 1 mM DTT, 5  µM GDP, 2.5 mM 
CaCl2) in the presence of 1.7 % thrombin.  GST and undigested GST-RhoA fusion 
protein were separated from RhoA via a glutathione-sepharose 4B column.  The flow-
through, which contained RhoA was concentrated, and loaded onto a size exclusion 
chromatography column (S200 16/60, Amersham Pharmacia Biotech) pre-equilibrated 
with gel filtration buffer (20 mM HEPES pH 8.0, 150 mM NaCl, 1mM  MgCl2, 
40 µM GDP, 1 mM DTT).  Fractions containing RhoA were pooled, concentrated to 
approximately 5 mg/ml and stored at –80 ºC.  The typical yield was 2.5 mg per liter of 
cell culture.  
 
3.2.10 Cloning, expression and purification of RhoA from a pMAL vector 
RhoA expressed from the pGEX-KG-RhoA plasmid contains 15 additional amino 
acids at the N-terminus.  To eliminate the possibility that these additional amino acids 
interfere with crystallization, RhoA was cloned from the pGEX-KG-RhoA vector (see 
3.2.2 ) into the modified pMAL expression vector pMALc2H10T, which encodes an N-
terminal MBP affinity tag followed by an H10 tag and TEV protease cleavage site 
(pMALc2H10T_RhoA, Figure 3.2.).  The pMALc2H10T vector was generated by inserting 
5' phosphorylated oligonucleotides (tcg ggc acc atc acc atc acc atc acc atc acc atg aaa acc 
tgt att ttc agg gag, aat tct ccc tga aaa tac agg ttt tca tgg tga tgg tga tgg tga tgg tga tgg tgc, 
Integrated DNA technologies) that encode the H10 tag and TEV protease cleavage site 
between the restriction sites AvaI and EcoRI of the pMALc2X vector (NEB).  
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RhoA was expressed from the pMALc2H10T_RhoA vector as an N-terminal 
fusion protein with MBP and an N-terminal hexahistidine tag.  Both, MBP and the H10 
tag can be cleaved with TEV protease.  Rosetta (DE3) pLysS cells (Novagen) carrying 
the pMALc2H10T plasmid were grown to OD600 = 0.6, induced with 1 mM IPTG at 30 ºC 
and harvested after 4-6 hrs by centrifugation at 3500 rpm in a Beckman Coulter Avanti J-
20 centrifuge, using a JLA 8.100 rotor.  The cell pellet was frozen in liquid nitrogen and 
stored at -80 ºC until purification. 
Lysis was done as described above (3.2.2) for RhoA expressed from the pGEX-
KG-RhoA vector except that lysis buffer contained 10 mM βME instead of DTT.  The 
supernatant was loaded onto a drip column containing Ni-NTA resin (Qiagen), which 
was pre-equilibrated with equilibration buffer (20 mM HEPES pH 8.0, 300 mM NaCl, 
10 mM Imidazole, 10 mM βME, 10 % glycerol, 10 mM MgCl2, 5 µM GDP).  After 
washing with 5 column volumes of equilibration buffer and 5 column volumes of wash 
buffer (equilibration buffer with 20 mM imidazole) protein was eluted in 1 ml fractions in 
elution buffer (equilibration buffer with 250 mM imidazole).  Fractions containing the 
MBP-RhoA fusion protein were pooled and dialyzed overnight against dialysis buffer 
(20 mM HEPES pH 8.0, 150 mM NaCl, 5 mM βME, 10 % Glycerol, 5 mM MgCl2, 5 µM 
GDP) in the presence of 2 % TEV protease.  RhoA was separated from MBP and 
undigested MBP-RhoA fusion protein by subjecting the dialyzed solution to another Ni-
NTA column.  The flow-through, which contained RhoA, was concentrated and loaded 
onto a size exclusion chromatography column as described in 3.2.2.  Fractions containing 
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RhoA were pooled, concentrated to approximately 5 mg/ml and stored at –80 ºC.  RhoA 
expressed from both, the pGEX-KG-RhoA and the pMALc2H10T_RhoA vectors showed 
smeared bands on SDS-PAGE gels (Figure 3.3b).  This phenomenon has been observed 
previously for Ras and Rho family GTPases and was thought to be due to oxidation of the 
GTPases [105].  
 
Figure 3.10:  Vector map of the expression vector for RhoA, pMALc2H10T_RhoA.  
RhoA was expressed as N-terminal fusion protein with maltose binding protein (MBP) 
followed by an H10 tag and the TEV protease cleavage site.  After cleavage with TEV 
protease RhoA contains additional three amino acids at the N-terminus.  Arrows indicate 
the start of the coding regions for the Ptac promotor (Ptac), lac repressor (lacIq), β-
lactamase (AmpicillinR), and maltose binding protein (malE). 
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Figure 3.11: Purification of RhoA using NiNTA columns.  The MBP-RhoA fusion 
protein was overexpressed in Rosetta (DE3) pLysS cells.  Cells were lysed with lysozyme 
in the presence of protease inhibitors.  The cell lysate was applied to a NiNTA column 
(NiNTA-1), the column was washed with 10 column volumes of buffer and the MBP-
RhoA fusion protein was eluted with buffer containing 250 mM imidazole.  
Subsequently, the eluate was dialyzed against buffer without imidazole and in the 
presence of 2 % TEV protease.  The digest, which contained MBP (43 kDa) and RhoA 
(21 kDa), was applied to a second NiNTA column (NiNTA-2).  The flow through from 
this column (Fb) contained RhoA and undigested MBP-RhoA fusion protein.  S: 
supernatant, P: pellet, Fa: flow through from NiNTA-1, W1: wash with lysis buffer, W2: 
wash with buffer containing 10 mM imidazole, E: eluate, D: digest, Fb: flow through 
from NiNTA-2.  
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Figure 3.12:  Gel filtration of RhoA.  The flow through of the NiNTA-2 column was 
concentrated and applied to a gel filtration column (S200 16/60, Amersham Pharmacia 
Biotech) pre-equilibrated with gel filtration buffer (20 mM HEPES pH 8.0, 
150 mM NaCl, 1 mM MgCl2, 40 µM GDP, 1 mM DTT).  RhoA eluted at a flow rate of 
1 ml/min and with an apparent MW of 19 kDa.  Fractions 46 to 57 were pooled.  
Unidgested MBP-RhoA and MBP eluted as a broad peak.  
 
3.2.11  Purification of the RhoA:DH/PH complex  
The DH/PH domains of LARG were mixed with a two-fold molar excess of 
RhoA and diluted 10-fold with complex buffer (20 mM HEPES pH 8.0, 150 mM NaCl, 
10 mM EDTA, 2 mM DTT).  After incubation for 10 min on ice, the complex was loaded 
onto a size exclusion chromatography column (S200 16/60, Amersham Pharmacia 
Biotech), which was pre-equilibrated with gel filtration buffer (20 mM HEPES pH 8.0, 
150 mM NaCl, 1 mM EDTA, 2 mM DTT).  Fractions containing the RhoA-DH/PH 




Figure 3.13: Chromatogram of the gel filtration of the RhoA-DH/PH complex.  The 
DH/PH domains were mixed with a two-fold molar excess of RhoA in buffer containing 
10 mM EDTA and incubated on ice for 10 min.  Subsequently the sample was loaded 
onto a gel filtration column and the protein was eluted at a flow rate of 0.5 ml/min.  The 
first peak corresponds to the DH/PH-RhoA complex and eluted at an apparent MW of 
44 kDa.  The second peak corresponds to excess RhoA and eluted at an apparent MW of 
19 kDa.  The gel confirms the presence of both, RhoA and the DH/PH domains in the 
first peak.  RhoA expressed from the pMAL and the pGEX vector shows two bands on 
SDS-PAGE gels.  
 
3.2.12 Crystallization of the RhoA-DH/PH complex 
Crystals of the RhoA-DH/PH complex were obtained by the hanging drop vapor 
diffusion method in which 1 µl of protein solution was mixed with 1µl of well solution at 
4 ºC.  Two crystal forms, single rods and plates that were comprised of several thin 
densely stacked plates (see Figure 3.5) could be grown with RhoA expressed from the 
pGEX-KG-RhoA as well as from the pMALc2H10T_RhoA vector.  Crystals grew in a 
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wide range of precipitant and buffer solutions (precipitants: PEG 400, PEG 8000, PEG 
10000, PEG 12000, MPEG 5000, buffers between pH 6.0 and 7.8: sodium formate, 
sodium phosphate, Bis Tris, MES, PIPES).  Several additives were tried but did not seem 
to alter the formation of crystals: 1 to 10 mM EDTA, 0.5 to 2 mM MgCl2, 1 to 3 % 
methanol, 1 % propanol, 0.4 to 1.4 M urea, 0.1 to 0.3 mM and 0.1 mM dodecyl 
maltoside, 5 to 15 % glycerol and 0.2 mM IP3.  Crystals could also be grown at room 
temperature with 15 % PEG 8000 and 10 % PEG 10000 as the precipitant.  Initial crystals 
grew as thin short rods and optimization of the crystallization conditions resulted in 
thicker and longer rods.  Crystals that grew as densly stacked plates could not be used for 
structure determination because they either cracked during harvesting or showed a highly 
mosaic diffraction pattern that could not be indexed.  The crystal used for structure 
determination was grown in well solution containing 11% PEG 8K, 0.6 M NaCl, 50 mM 
sodium phosphate pH 7.4, and 5 mM EDTA.  The presence of both RhoA and the DH/PH 
domains, and not just either protein in the crystals, was verified by crushing the crystals 
in wash buffer, washing the crystals, running the solutions on a gel and staining with 
silver stain.  This procedure showed bands at the corresponding molecular weights for 
RhoA as well as the DH/PH domains.  Complex crystals belong to spacegroup C2 and 
have unit cell dimensions of a = 294.9 Å, b = 95.0 Å, c = 157.0 Å and β = 94.0 º.  The 
Matthews coefficient indicated that there are 4 to 9 complex molecules per asymmetric 
unit (71 to 35 % solvent content, respectively).  Structure determination subsequently 
revealed that the complex crystallized as a tetramer with pseudo-C4 non-crystallographic 
symmetry and contains four molecules per asymmetric unit (VM  = 4.3 Å3 Da-1).  
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Figure 3.14:  Crystals of the LARG DH/PH domains-RhoA complex.  (a) Initial 
crystals grown as needles.  (b) Initial crystals grown as stacked plates.  (c) A single 
crystal grown under optimized conditions.  
 
3.2.13  Harvesting of RhoA-DH/PH complex crystals 
Complex crystals grew in two crystal forms that were prone to cracking during 
crystal harvesting.  The long rods were often attached to the coverslip and cracked when 
cryosolution was added to the drop.  The thin, stacked plates either separated during 
harvesting or cracked.  Instead of adding cryoprotectant solution to the drop complex 
crystals were transferred through a series of solutions containing increasing 
concentrations of cryoprotectant.  Several harvesting conditions had to be explored, 
including 20 % glycerol in combination with 10 % PEG 8000, 15 % ethylene glycol, and 
25 % ribose.  15 % PEG 400 in combination with 15 % PEG 8000 seemed to retain the 
best diffracting crystals.  The cryoprotectant solution, that was used to harvest the crystal 
from which the best data set was collected contained 15 % PEG 400, 15 % PEG 8000, 
0.6 M NaCl, 50 mM sodium phosphate pH 7.4, 20 mM HEPES, pH 8.0, 2 mM DTT, and 
5 mM EDTA.  Cryoprotected crystals were flash frozen in liquid nitrogen and stored in 
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liquid nitrogen or propane for later data collection.  Alternatively, for immediate data 
collection, cryoprotected crystals were flash frozen in the cryostream. 
 
3.2.14  Data collection and processing of RhoA-DH/PH complex crystals 
The initial data set of the DH/PH-RhoA complex crystals (rhoAdhph50) was 
collected using CuKα radiation on a MAR345 imaging-plate detector (diffraction to 
4.0 Å spacings).  The temperature was maintained at 95 K with an Oxford Instruments 
Cryojet.  The data set for the final structure determination (rhoAdhph92) was collected on 
a Quantum 210 CCD detector (ADSC) at beam line 8.2.1 of the Advanced Light Source 
(ALS) in Berkley, CA (diffraction to 3.2 Å spacings).  The diffraction pattern was highly 
anisotropic with diffraction to 3.2 Å in the best direction (c axis), but only 3.75 Å and 
4 Å along the a and b axes, respectively.  Data were reduced and scaled using the 
HKL2000 package [94]. A sigma cut off of -1 was applied.  
 
 
Table 3.7: Scaling statistics for the rhoAdhph92 crystals.  Reflections were integrated 




3.2.15  Structure determination of the RhoA-DH/PH complex 
The 3.2 Å crystal structure of the LARG DH/PH-RhoA complex was determined 
by molecular replacement using the LARG DH domain (see above) modeled in complex 
with RhoA from the Dbs-RhoA complex structure (PDB code: 1LB1), as a search model.  
Molecular replacement was performed with the program MOLREP of the CCP4 suite 
[95].  The best solution was achieved by searching for 4 molecules per asymmetric unit.  
The solution had a peak height (RF/σ) of 7.03 and an initial R factor of 52 and correlation 
coefficient of 42.  The LARG DH/PH domains in complex with RhoA could not be used 
as a search model, which was reflected in an R factor and correlation coefficient of 62 
and 25, respectively.  This is not surprising because the relative disposition of the PH and 
DH domain in RhoGEFs differs considerably (Fig. 3.19).  The resulting electron density 
map allowed placement of the PH domain from the DH/PH structure (see above).  Some 
loop regions within the DH/PH domains, for which electron density was not interpretable 
in the DH/PH crystal structure, showed interpretable electron density in the A and C 
chains of the complex crystals.  This was due to stabilization of these regions by either 
complex formation with RhoA, in case of the N-terminal extension and the β5-β6 loop, 
or by crystal contacts, in case of the N-terminus of the PH domain (999-1008), the β1-β2 
loop (1029-1035), the insert in the β4 strand (1062-1073), and the C-terminus of the PH 
domain (1136-1138) (see Fig. 3.15, 3.16, 3.18).  The DH/PH domains in the complex 
structure were therefore used as a model to build these loop regions in the DH/PH 
structure.  However, Asp765, residues 1002-1005 in the βN-3/10N loop, and residues 
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1064-1074 in the insert region in the β4 strand could not be modeled in either the 
complex or in the DH/PH structure.  
 
3.2.16  Refinement of the RhoA-DH/PH complex structure 
The structure was refined with the programs CNS and REFMAC with TLS 
refinement to final Rwork and Rfree of 25 and 31%, respectively (Table 3.5).  Non-
crystallographic symmetry (NCS) constraints were employed.  Initially “tight” four-fold 
restraints were used and as differences between the chains became apparent, relaxed 
restraints were used, and ultimately removed.    
 
Analysis of crystal packing 
The DH/PH-RhoA complex crystallized as a tetramer with pseudo-C4 non-
crystallographic symmetry.  The C4 symmetric contacts between subunits involve mainly 
the N-terminal extension and the α4 segment and bury an unconserved tryptophan side 
chain Trp953 in the α5-α6 loop of the DH domain.  This tryptophan is exposed and not 
ordered in the DH/PH domains structure. Although oligomers that associate with the 
membranes tend to have cyclic symmetry, this tetramer is not expected to be 
physiologically significant.  Furthermore, the DH/PH-RhoA complex eluted as a 
monomer from gel filtration columns.  
Inspection of the electron density map showed four molecules per asymmetric 
unit arranged as a pseudo-tetramer.  The plane of the tetetramer is about 40° offset 
relative to the x-axis of the unit cell.  Monomer A and C show well defined electron 
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density in some problem areas, especially in the loop between DH and PH domains and 
the N-terminal region. These two monomers are involved in crystal contacts with 
residues of the DH domain and RhoA. Monomers E and F do not show electron density 
in these areas and they are involved in crystal contacts through their PH domains. The 
interactions within the pseudo-tetramer are entirely through DH-DH domain contacts. 
The interactions between pseudo-tetramers are formed by DH-RhoA contacts as well as 






3.3   Structure Interpretation and Discussion 
3.3.1  The LARG DH/PH domains 
The core of the LARG DH domain is, like other RhoGEF DH domains, 
comprised of six major helical segments, in which segments 2, 3, and 5 contain kinks and 
are subdivided in a series of short α-helices (Fig. 3.15).  The most novel structural feature 
of the LARG DH domain is an N-terminal extension (residues 766-781) that has not been 
observed in previously determined structures of DH domains.  This extension forms a 
small subdomain, comprised of a loop and two short α-helices (αN1: residues 769-773, 
αN2: residues 775-781).  The αN1/αN2 subdomain was highly mobile in the DH/PH 
structure, and was traced only after structure determination of the DH/PH-RhoA complex 
(see below).  Sequence analysis indicates that the N-terminal extension is conserved in 
the Lbc family of RhoGEFs, which specifically exchange nucleotides on RhoA (Fig. 
3.20).  The αN1/αN2 subdomain seems to be stabilized by a hydrophobic core that 
centers on Trp769, a residue that is invariant in the Lbc family.  Furthermore, conserved 
residues from αN1, αN2, α1, and the α2-α3 loop participate in the hydrophobic core.  
The LARG PH domain is a flattened, anti-parallel β-barrel, capped on one end by 
a C-terminal alpha helix (αCT) (Fig. 3.15 and 3.18).  Compared with the LARG DH 
domain, the PH domain has substantially higher temperature factors, indicating relatively 
high mobility of the domain in the crystal lattice.  Like other RhoGEF PH domains, the 
LARG PH domain has an N-terminal extension, comprised of an α-helix (αN) that is an 
extension of the α6 segment of the DH domain, followed by a β-strand (βN) and then a 
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3/10 helix (N3/10).  Residues from all secondary structure elements in the extension form a 
large hydrophobic core with the β2-β3 sheet, which has a high content of aliphatic 
hydrophobic residues.  A similar hydrophobic core is observed in the Tiam, Dbs, 
intersectin, and SOS DHPH domains, where it is comprised of aromatic as well as 
aliphatic residues.  The βN-strand of LARG and all other DHPH domains forms a β-sheet 
with the β4-strand.  The PH domain of Tiam is the only RhoGEF PH domain that does 
not have a βN strand.  However, hydrophobic residues in the α6 strand seem to be taking 
over the role of the βN strand and are interacting with β4 [5].    
Location of the xenon and bromide sites in the DH/PH domains 
To verify the validity of the determined xenon and bromide sites, their location 
within the DH/PH fragment was studied.  Xenon atoms usually occupy hydrophobic 
pockets and bromide ions positively charged pockets.  Two xenon sites were found in the 
DH domain (Xe1 and Xe3) and one xenon site in the PH domain (Xe2).  The strongest 
peak corresponds to the xenon atom in the PH domain (Xe2).  This xenon atom lies in a 
hydrophobic pocket made by a conserved tryptophan in the PH domain (Trp1123) and two 
leucine residues (Leu1026, Leu1097).  The second relatively strong peak (Xe1) corresponds 
to a xenon atom in the DH domain that lies in a highly conserved hydrophobic core, 
which holds together α1, α3, α4, and α5 and therefore stabilizes the helical bundle.  The 
weakest peak (Xe3) corresponds to a xenon atom that lies in a hydrophobic pocket 
comprised of residues from the α3 and α4 helix segments (Gln902, Gln909, Val912, Gln913).  
The sodium bromide lies in a postively charged groove on the surface of α3, that is 




























































































































































































































































































































































































































































































































































3.3.2  The LARG DH/PH domains in complex with RhoA 
DH/PH-RhoA crystallized as a tetramer with pseudo-C4 non-crystallographic 
symmetry (Fig. 3.16).  The four DH/PH domains-RhoA complexes were defined as AB, 
CD, EF, and GH chains.  The DH/PH domains of two protomers (chains A and C) are the 
best ordered.  The C4 symmetric contacts between subunits bury the side chain of Trp953, 
which occurs in the β5-β6 loop of the DH domain.  Although oligomers that associate 
with membranes often have cyclic symmetry, this tetramer is not expected to be 
physiologically significant, in part because Trp953 is not conserved in other RH-RhoGEFs 
and the RhoA monomers are not consistently oriented towards the same plane.  
The major contact regions with RhoA are in the DH domain.  Contacts between 
the α1 and α5 helical segments of the DH domain and switch I of RhoA, and contacts 
between the α6 helical segment and switch II define the basis for the catalysis of 
nucleotide exchange (see 3.3.7).  Contacts of the α4-α5 loop of the DH domain with the 
β1-β2-β3 sheet of RhoA and contacts between the α5 helical segment and the β3 strand 
of RhoA dictate substrate specificity (see 3.3.11).   
Residues 2-181 of RhoA are observed in the most well-ordered RhoA subunit (B) 
of the tetramer, and the backbone conformation of RhoA is essentially the same as that of 
RhoA in complex with Dbs (0.6 Å r.m.s. deviation) [3].  The changes seen in DH/PH-
bound RhoA compared to nucleotide-bound RhoA are in the switch I and switch II of 
RhoA, as well as the P-loop and the 116GXKXDL121 motif.  There are two structures of 
GDP bound RhoA, one including Mg2+ [106] and one without Mg2+ [1].  Comparison of 
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these structures reveals expected conformational changes in the switch II region, which 
plays an important role in coordinating the Mg2+ ion.  In the RhoA-GDP structure 
(without Mg2+), switch II is collapsed into the Mg2+ and γ-phosphate binding sites.  A 
similar conformation of switch II is seen in the complex structure with the LARG DH/PH 
domains.  The conformation of switch I in the RhoA-GDP structure was unexpectedly 
different from the RhoA-GDP-Mg2+ structure.  Switch I is in a position similar to what 
has been observed for switch I of Ras in the Ras-SOS structure [2], where it is completely 
removed from the nucleotide binding site (the  largest displacement is 19 Å for Val33).  
Switch I in the DH/PH-RhoA structure is in a similar orientation as in the RhoA-GDP-
Mg2+ structure, although interactions of switch I with the LARG αN1/αN2 subdomain 
leave the nucleotide binding pocket in a slightly more exposed position compared to 
RhoA-GDP-Mg2+ (displacement for Val33 is 6.8 Å).  
Switch I has increased B-factors compared to the remaining residues of RhoA, 
which indicates high mobility of this region.  Increased B-factors in switch I have been 
observed in other GTPases in complex with DH/PH domains.  However, in these 
structures the increase of B-factors in this region is much more pronounced, indicating 
that the N-terminal extension in the LARG DH/PH domains might contribute to the 
stability of this region.  The insertion region of RhoA (Fig. 1.1), which is implicated in 
effector binding [33, 34] is completely exposed to solvent and indicates that the 
formation of a signaling complex is possible, in which RhoA can bind effector molecules 
while it is activated by the DH/PH domains.  The nucleotide binding site of RhoA 
showed strong positive electron density in the 2Fo-Fc map in place where the α-phosphate 
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is located in nucleotide bound RhoA.  The density was therefore modeled as a phosphate 
because crystals were obtained in phosphate buffer (3.2.5).   
 
Figure 3.16:  The DH/PH-RhoA complex crystallized as a tetramer with pseudo-C4 
non-crystallographic symmetry.  The four DH/PH domains-RhoA complexes were 
defined as AB, CD, EF, and GH.  The DH/PH domains of two protomers (A and C) are 
relatively well ordered compared with those of the DH/PH structure.  This tetramer is not 
expected to be physiologically significant, because the symmetry contacts between 
subunits are not conserved in other RH-RhoGEFs, the RhoA monomers are not 
consistently oriented towards the same plane, and the complex elutes as a monomer from 
a gel filtration column.  The insertion region of RhoA, which is implicated in effector 
binding [33, 34] is completely exposed to solvent and indicates that the formation of a 
signaling complex is possible, in which RhoA can bind effector molecules while it is 
activated by the DH/PH domains.
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3.3.3  Changes in the LARG DH/PH domains upon complex formation 
The overall conformation of each of the individual DH and PH domains in the 
complex is similar to their counterparts in the DH/PH structure (r.m.s. deviations of 0.995 
and 0.749, respectively).  Conformational changes in the DH domain occur in the N-
terminal extension, the α4-α5 loop, and the DH/PH junction.  These regions directly 
engage RhoA.  The N-terminal extension is pulled towards RhoA and residues Asn768 and 
Glu790 are re-oriented to provide a more compatible surface for the interaction with RhoA 
(Fig. 3.17).  The α4-α5 loop is pushed away from RhoA by about 1.6 Å due to steric 
interference with the RhoA N-terminus and the RhoA β2-β3 sheet.  
Side chains of the DH domain in the DH-RhoA binding interface are essentially 
unchanged, except for two residues in the α5 and α6 segments (Gln935, Asn975, 
respectively), whose side chains are altered to provide a more optimal binding interface 
for the RhoA residues Asn41 and Arg68, in the effector loop and switch II, respectively.  
Both, Gln935 and Asn975 are highly conserved in the Dbl family DH domains and 
mutations of these residues in the Dbl and Trio DH domains severely impaired nucleotide 
exchange activity [8, 9].  The conformation of the PH domain is essentially unchanged, 
although the loops have become better ordered. 
 
Changes in the DH-PH junction 
The structures of the LARG DH/PH domains in the unbound form as well as 
bound to their substrate GTPase RhoA have been determined.  The two structures now 
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provide evidence for the proposed importance of the C-terminal region of the Tiam DH 
domain in nucleotide exchange [5] and for the severely diminished nucleotide exchange 
activity of mutants in the DH-PH junction of Dbl [107].  Although the conformation of 
the individual DH and PH domains in the complex structure are similar to their 
equivalents in the DH/PH structure, the DH-PH junction shows striking differences.  
Upon complex formation with RhoA the PH domain is collapsed relative to the DH 
domain, by approximately 30˚, as if the two domains are embracing RhoA (Figure 3.15).  
This conformational change is similar in all four complexes of the crystal structure and 
mainly involves the hinge between the DH and PH domains at the end of the α6 helix 
spanning residues 975 to 986.  Because each complex has a unique crystalline 
environment, the observed collapse is not likely an artifact of crystal packing.  Each of 
the PH domains adopts a slightly different orientation with respect to the DH domain.  
However, each PH domain maintains similar contacts with RhoA.  Two scenarios can be 
envisioned that would cause the observed conformational change of the DH/PH domains 
upon binding RhoA.  Firstly, interactions of Arg68 in RhoA with Glu982, which is highly 
conserved throughout the Dbl family, and with Asn983, could cause the PH domain to be 
rotated (Fig. 3.17).  Secondly, the PH domain could rotate upon binding to either 
membranes or other regulatory proteins, which then could favor RhoA binding.  The 
rotation of the PH domain causes one new contact to be established between the DH and 
the PH domain that is not present in the DH/PH structure.  Lys979 hydrogen bonds to the 
backbone carbonyl of Ile1021 in the β1 strand of the PH domain.  His814 in Dbs is the 
equivalent residue to Lys979 in LARG and is also involved in contacts with the Dbs PH 
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domain (Tyr889) [4].  His814 in Dbs forms additional contacts with RhoA and mutating 
either His814 or Tyr889 resulted in highly diminished exchange activities, confirming the 
importance of DH-PH domain contacts in nucleotide exchange.  
 
Figure 3.17: Changes at the DH-PH junction upon complex formation.  Upon 
complex formation with RhoA, the PH domain collapses relative to the DH domain and 
forms indirect (via the DH domain) contacts with RhoA at the DH-PH junction.  
Residues of the β1 strand of the PH domain interact with C-terminal residues of the α6 
segment that directly contact Arg68 of RhoA (PH Met1020-DH Asn983, PH Glu1023-DH 
Arg986).  A similar role of the PH domain in supporting interactions of the DH domain 
with RhoA has been seen in Dbs and confirmed by site directed mutagenesis [4].  The 
rotation of the PH domain causes one new contact to be established between the DH and 
the PH domain that is not present in the DH/PH structure.  Lys979 hydrogen bonds to the 
backbone carbonyl of Ile1021 in the β1 strand of the PH domain.  The equivalent residue 
in Dbs, which also exhibits PH domain-assisted nucleotide exchange, interacts with a PH 
domain residue and is crucial for its catalytic activity [4]. 
.
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3.3.4   The LARG DH and PH domains in comparison to other RhoGEFs 
The DH domain 
The most distinct structural feature of the LARG DH domain is an N-terminal 
subdomain that might be present throughout the Lbc family RhoGEFs (Fig. 3.10).  
Intersectin is an outlier in this family, which specifically exchanges nucleotides on 
Cdc42.  Although Trp769, a residue at the center of the hydrophobic core of the 
subdomain, is also conserved in intersectin, intersectin has a two amino acid deletion in 
the N-terminal extension (residues equivalent to LARG Leu772 and Val773) and several 
substitutions (arginine substituted for Ile786, glycine substituted for Glu790) that could 
abrogate the formation of an equivalent N-terminal subdomain.  The construct that was 
used in the structure determination of the intersectin DH/PH domains did not contain the 
entire N-terminal extension [3].  However, the three residues N-terminal to α1 in 
intersectin are superimposable onto αN1 of LARG.   
When superimposed onto the Dbs [3, 4], intersectin [3], and Tiam [5] DH 
domains the most prominent structural variations in the LARG DH domain are in the α2-
α3 and the α4-α5 loop, as well as in the C-terminus of α6 (Fig. 3.16).  The α2-α3 loop in 
the LARG and intersectin DH domains has a six residue insertion with respect to the Dbs 
DH domain.  In LARG this extension allows the α2-α3 loop to contribute a hydrophobic 
residue (Val860) to the N-terminal subdomain (Fig. 3.10).  In intersectin, Val860 is 
substituted with a proline, which could also contribute to a hydrophobic core and stabilize 
a subdomain.  The α2-α3 loop of Tiam has a 15 residue insertion compared to the Dbs 
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DH domain, which forms a short 3/10 helix.  The functional implications of this extended 
α2-α3 loop in Tiam are not obvious from the structure.   
The α4-α5 loop is one of the primary specificity determining regions of the DH 
domain (see 3.3.8) and accommodates the N-terminal region of the GTPase including 
Arg5, which is substituted by shorter residues in Rac1 (Ala3) and Cdc42 (Thr3).  In the 
LARG structure the segment encompassing the α4-α5 loop, the α4 helix and the C-
terminal part of the α3 helix, is further away from RhoA by about 2.5 Å compared to the 
Tiam-Rac1 and Dbs-Cdc42 structures.  The N-terminus of the GTPase therefore seems to 
determine the position of this region relative to the helical bundle.   
The C-terminus of the α6 segments of RhoGEF DH domains constitutes the hinge 
region between the DH and the adjacent PH domain and the structural variations in this 
region determine the role of the PH domain in nucleotide exchange (see 3.3.3 and 3.3.9).  
The α6 segments of Dbs and Tiam are about 2.5 turns shorter than that of LARG and its 
closest homolog intersectin.  This allows the adjacent PH domain in Dbs to make direct 
contacts with its substrate GTPase.  These contacts are neccessary for full catalytic 
activity of Dbs in vivo [88] (see 3.3.9).  However, such contacts were not observed in the 
Tiam-Rac1 structure, due to a completely different arrangement of the Tiam PH domain 
relative to its DH domain.  Although, the α6 segment of the LARG DH domain is longer 
than the one in Dbs, a direct contact of the PH domain with RhoA is present due to a 7 Å 
translation of the PH domain towards RhoA compared to the Dbs PH domain (see 3.3.9).  
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The LARG DH domain has a three-residue insertion (Gly874, Ala875, Gly876) that 
forms a bulge at the junction between α3a and α3b.  This insertion is present throughout 
the Lbc family, with the exception of intersectin.  However, the residues that comprise 
this insertion are not conserved.  
The PH domain 
The PH domain of LARG has notable structural differences from other RhoGEF 
PH domains.  The β3-β4 loop of LARG is an abrupt β-turn, whereas in the Dbs-Cdc42 
and Tiam-Rac1 complexes the analogous loop is extended by 7 and 25 amino acids, 
respectively.  In the case of Dbs, the loop forms specific contacts with Cdc42 (Fig. 3.19).  
While Dbs has a continuous β4 strand, intersectin has a three-residue bulge (residues 
1515 to 1517) and LARG has a disordered 18-residue loop (residues 1060 to 1077) (Fig. 
3.18).  The function of this insertion in LARG and other RH-RhoGEFs is not known, 
although it projects towards what is anticipated to be the membrane binding surface of 
the PH domain.  It therefore could be involved in membrane association.  Among 
RhoGEF PH domains, the loop connecting βN and N3/10 is highly variable.  In the case of 
LARG, it consists of an 18-residue loop that contains an extra helix (αNb, residues 1005-
1013).  
The region between the end of αNb and the β1 strand as well as most of the β1 
strand show a high degree of sequence conservation in the family of RH-RhoGEFs.  This 
region is involved in contacts with the α6 segment and contains many residues that 
comprise the hinge region between the DH and the PH domain (Fig. 3.17).  This region 
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therefore determines the relative arrangement of PH to DH domains, which might be of 
importance for optimal orientation of the RhoGEF at the plasma membrane with respect 
to RhoA.  
Little is known about the membrane association and phospholipid binding 
capacities of RH-RhoGEF PH domains.  Results from a modeling study by Blomberg and 
Nilges [108] suggested that DH domain-associated PH domains (i.e. Lbc, Cdc24, Ect2, 
Unc-89, Scd1) might have a reverse electrostatic surface potential compared to PH 
domains that are known to bind phospholipids.  Modeling of these RhoGEF PH domains 
predicted that the regions, usually involved in phospholipid binding, would have a strong 
negative instead of a positive potential.  This prediction was confirmed for the Unc-89 
PH domain, whose structure revealed that one of the known phosphoinositol binding sites 
between the β1-β2 and β3-β4 loops is occluded and lined by hydrophobic and negatively 
charged residues [109].  This study suggests that RhoGEF PH domains mainly serve as 
protein-protein interaction domains rather than membrane association domains.  
However, the LARG PH domain exhibits an electrostatic surface potential similar to PH 
domains that are known to bind phospholipids.  The β1-β2 loop and the β5 strand have a 
positive surface potential.  Also the region at the base of the β4 insertion is positively 
charged (Figure 3.18).  Although, LARG and other RhoGEF PH domains do not posses a 
high-affinity 3-phosphoinosite binding motif that was proposed previously [110], the 
intersectin, Dbs and Tiam PH domains were found to bind phospholipids with low 
affinity (5-10 µM) [111].  The LARG PH domain has a possible binding site for 
IP(1,4,5)3 (Fig. 3.18) that is located between the β1-β2 loop and the β3-β4 loop and 
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comprised of β4-strand resdidues (Gln1051, Gln1053, Arg1056, Arg1060) that are highly 
conserved in the Lbc family of RhoGEFs.  
 
Figure 3. 18:  (A) Electrostatic surface potential of the LARG PH domain.  The 
electrostatic surface potential was generated with Swiss pdb viewer [112] and is 
contoured at ±1.5 kT.  The alpha carbon trace of the PH domain is shown in green.  The 
electrostatic surface potential of the LARG PH domain is similar to the one of PH 
domains that are known to interact with membranes.  (B) The structural features of the 
LARG PH domain.  Like other RhoGEF PH domains the LARG PH domain has an N-
terminal extension comprised of an α-helix (αN) that is an extension of the α6 segment 
of the DH domain, followed by a β-strand (βN) and then a 3/10 helix (N3/10).  The LARG 
PH domain has a conserved positively charged patch (Gln1051, Gln1053, Arg1060) that could 
interact with inositol phosphates, and a conserved hydrophobic patch (yellow side chains, 
Leu1086, Ala1091, Phe1098, Ile1100, Ala1107, Ile1109) that could be used as a docking site for 
regulatory proteins.  This hydrophobic patch is involved in crystal contacts in both the 
DH/PH and the DH/PH-RhoA complex crystals.  
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The relative orientation of PH to DH domains  
The relative orientation of PH to DH domains in RhoGEFs varies, and seems to 
dictate the involvement of the PH domain in catalysis.  PH domain-assisted nucleotide 
exchange in vitro has been shown for Dbs [4] and LARG [54].  In both structures the PH 
domains are in similar orientations and have direct and indirect (via the DH domain) 
contacts with the GTPase.  This is in contrast to the intersectin PH domain, which does 
not contact the GTPase and does not assist nucleotide exchange in vitro [3, 113].  The α6 
segment of LARG is by 10 residues longer than the one in Dbs, or about 2.5 helical turns, 
and thus the PH domain of LARG is translated about 13 Å along the length of the α6 
segment compared to that of Dbs (Fig. 3.16).  However, the LARG PH domain is also 
translated by about 7 Å towards the GTPase, relative to the Dbs PH domain.  This allows 
the LARG PH domain to make direct interactions with RhoA via the N-terminus of its 
αCT.  The PH domain of intersectin is similarily translated along the α6 segment as that 
of LARG, however, it is oriented differently and does not have direct contacts with 
Cdc42, neither does it support contacts of the DH domain with Cdc42 [3].  While in vitro 
studies confirm that the intersectin PH domain does not play a role in Cdc42 binding or 
catalysis, in vivo the PH domain is necessary for full catalytic activity [113].  This 
suggests that regulation of the intersectin PH domain, possibly by membrane binding or 
other signaling domains or proteins, contributes to DH/PH activity in vivo, which might 
be a mechanism that is generally used by RhoGEFs.   
The Tiam PH domain in the Tiam-Rac1 complex is rotated away from the 
GTPase so that its N3/10 helix makes contacts with residues from the α3 and α6 segments 
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of the DH domain [5].  These contacts are conserved in the Sif GEFs, which are close 
homologs to Tiam and hints against the possibility that they are caused by crystal packing 
artifacts.  The most divergent arrangement between PH and DH domains is seen in the 
SOS structure, where the PH domain is rotated towards the α1 and α5 segments of the 
DH domain and occludes the GTPase binding site [6].  Because the SOS DH/PH 
fragment is not active in vitro and only activated in vivo when co-expressed with 
activated Ras [86], the structure could represent a DH domain that is auto-inhibited by its 
adjacent PH domain.  It is believed that the auto-inhibition is relieved upon binding of 






















































































































































































































































































































































































































































































































3.3.5 The αN1/αN2 subdomain  
Sequence analysis indicates that the αN1/αN2 subdomain is conserved in the Lbc 
family of RhoGEFs, which specifically exchange nucleotides on RhoA (Fig. 3.10).  The 
αN1/αN2 subdomain seems to be stabilized by a hydrophobic core that centers on Trp769, 
a residue that is highly conserved in the Lbc family (Fig. 3.17).  Furthermore, residues 
from αN1 (Val773), αN2 (Val777, Leu778, Leu781), α1 (Ile786, Gln789, Glu790), and the α2-α3 
loop (Ser859, Val860) participate in stabilizing the hydrophobic core.   
 
The αN1/αN2 subdomain interacts with the effector loop of RhoA (Lys27, Val33) 
Sequence analysis indicates that the αN1/αN2 subdomain of LARG is highly 
conserved among the Lbc subfamily of RhoGEFs, nearly all of which are selective for 
RhoA (Fig. 3.17), indicating that it might be specificity determining.  Interestingly, this 
subdomain interacts with the effector loop/switch I of RhoA and this interaction might be 
the basis for the more pronounced exposure of the nucleotide binding pocket in the 
LARG DH/PH domains compared to other DH/PH domains that do not posses an N-
terminal extension.  This could indicate that the subdomain is necessary for catalysis by 
promoting the formation of the nucleotide-free form of RhoA.  The principal contacts are 
between Val33 of RhoA, a residue conserved as glutamate in other Rho GTPases, and the 
side chains of Asn768 and Gln770 of αN1, and between Tyr34 and Glu790 of the α1 helix 
(Fig. 3.17).  Although disordered in the crystal structure, the side chain of Lys27 is in 
close proximity to the backbone carbonyls of Pro766 and Pro767 of LARG.  Lys27 is 
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conserved as threonine in other GTPases.  Therefore, LARG potentially has an additional 
GTPase-selecting determinant at the N-terminus of its DH domain.  In support of this 
hypothesis, an interesting observation was made when an LARG DH/PH domain 
construct (residues 785-1140), that lacked the N-terminal extension, was studied [54].  
This construct showed some nucleotide exchange on Cdc42.  If the N-terminus was 
indeed specificity determining, it would suggest that intersectin, which is the only 
member of the Lbc family that is specific for Cdc42 and not RhoA, does not have this N-
terminal subdomain.  Intersectin has a two-residue deletion within the N-terminal 
extension with respect to LARG, and several amino acid substitutions in α1 (a glycine 
substituted for Glu790 and arginine substituted for Ile786 in LARG) that could potentially 
abrogate formation of an analogous N-terminal subdomain.  In the crystal structure of the 
intersectin-Cdc42 complex, only some of the residues corresponding to the N-terminal 
extension (residues 1229 to 1232) were present in the recombinant protein used for 
structure determination.  Even so, these four residues are superimposable with their 
equivalents in the LARG N-terminal subdomain.  
 
A residue of the αN1/αN2 subdomain (Glu790) exhibits an altered conformation 
upon complex formation 
Compared to the unbound DH/PH domains, Glu790 dramatically alters its 
conformation upon complex formation with RhoA.  Glu790 participates in a hydrogen 
bonding network with the backbone amides of Trp769 and Gln770 as well as with the 
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Gln770 side chain and packs against Tyr34 of switch I, which is sandwiched between 
Glu790 and Pro32 of RhoA.  The changed conformation of Glu790 seems to be a result of 
steric interference with the backbone carbonyl of Val33 of RhoA.  The altered 
conformation of Glu790 might be structurally necessary for two reasons.  First, the 
interactions of Glu790 with the N-terminal subdomain might be necessary for its 
stabilization.  Indeed, αN1 has significantly lower B-factors in the complex structure.  
Second, the N-terminal subdomain might be necessary to restrict the conformation of 
Glu790, to a compatible conformation for RhoA binding.  The lack of an N-terminal 
subdomain might leave Glu790 in an extended conformation that is not compatible with 
RhoA binding or does not provide a beneficial binding surface for Tyr34.  Interestingly, 
Glu790 is conserved in the Lbc family except for intersectin, where is a glycine (Gly1240).  
This substitution leads to a slightly different conformation of Tyr32 in Cdc42 (equivalent 
to Tyr34 in RhoA), which is now sandwiched between the backbone of Gly1240 and Pro30 
(equivalent to Pro32 in RhoA).  The van der Waals interaction of Glu790 with Val33 might 
be specificity determining because Val33 is substituted by a glutamic acid in Cdc42, 
which would cause steric repulsion.  The substitution of this residue for a glycine in 
intersectin might be necessary for its interaction with Cdc42.    
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Figure 3.20: (A) A novel subdomain, the αN1/αN2 subdomain, has been revealed at 
the N-terminus of the LARG DH/PH domains.  The αN1/αN2 subdomain contains a 
hydrophobic core, that is comprised of residues from the αN1 and αN2 helices as well as 
the α2-α3 loop, and is centered on Trp769.  These residues are conserved in the Lbc 
family of RhoA specific RhoGEFs. Intersectin is an outlier in this family because it is 
specific for Cdc42 and it has a two residue deletion and several substitutions that could 
abrogate the formation of an equivalent subdomain.  (B) The αN1/αN2 subdomain 
interacts with switch I of RhoA.  Glu790 packs agains Val33 and Tyr34 and changes its 
conformation upon complex formation.  Glu790 is substituted with a glycine in intersectin, 
which might be necessary for its specificity for Cdc42.  (C) Sequence alignment of the 
region N-terminal to the DH domain in Lbc family RhoGEFs and Vav.  
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3.3.6  Structural basis for LARG catalyzed nucleotide exchange 
 Like other GEFs, LARG does not directly contribute residues that help to eject the 
the nucleotide, instead it changes the magnesium and nucleotide coordinating sites of the 
GTPase to favor nucleotide release and stabilize the nucleotide free form of the GTPase.  
The LARG-RhoA interface is made primarily by contacts between residues in the α1, α5, 
and α6 segments of the DH domain with switch I and II of RhoA, as observed in 
previous GEF-GTPase structure.  These contacts are highly conserved and define the 
basis for disruption of the magnesium binding site and exposure of the nucleotide binding 
site of RhoA.  Upon complex formation, switch I and switch II of RhoA are reorganized 
such that nucleotide release is favored (Fig. 3.18).  Switch II is reorganized mainly by 
hydrophobic contacts between Tyr66 in RhoA and the α5 and α6 segments.  The side 
chains of Ala61 and Glu64 in switch II are re-oriented into the magnesium and γ-phosphate 
binding sites, respectively (Fig. 3.18).  Glu64 is now in hydrogen bonding distance to 
Lys18 of the P-loop.  Lys18 and Glu64 are highly conserved in small GTPases and are 
crucial for nucleotide exchange reactions [114, 115] possibly due to their contribution to 
stabilizing the nucleotide-free state of the GTPase.  Switch I, which in the GDP bound 
form of RhoA coordinates the magnesium and nucleotide binding sites, is re-arranged by 
interactions with the α1, α5a and αN2 helices of the DH domain, resulting in exposure of 
the nucleotide binding site.  Glu935, Lys939, and Leu943, three highly conserved residues in 
the α5 segment of DH domains, would sterically interfere with the switch I loop in the 
GDP bound form of RhoA.  It therefore, appears as if these residues push switch I away 
from the DH domain.  The changed conformation of switch I seems to be stabilized by 
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interactions with α5a1 and αN2, involving interactions of Glu794 of α1 with the backbone 
amides of Thr37 and Val38 of RhoA.  This glutamic acid is highly conserved in RhoGEFs, 
and is also the major contact residue between the DH/PH domains and switch I in the 
Tiam-Rac1 [5], Dbs-RhoA [3], and intersectin-Cdc42 structures [3].  Thr37 of switch I, 
which coordinates the magnesium ion in the Rho-GDP-Mg2+ structure [106] (Fig. 3.18) is 
in hygrogen bonding distance to Asn946 and removed from the magnesium binding site.  
The interactions of the N-terminal subdomain in LARG with switch I are probably 
responsible for a slightly more exposed nucleotide binding site of RhoA compared to the 
other DH/PH-GTPase complex structures, where no N-terminal extension was observed.   
In previously determined DH/PH-GTPase structures the only structural basis for 
nucleotide expulsion is interference with the magnesium binding site by switch II 
residues and exposure of the nucleotide binding site due to re-arrangement of switch I 
(Fig. 3.18).  The nucleotide binding pocket in these structures is otherwise undisturbed.  
However, in the LARG DH/PH-RhoA complex there are also interferences with the 
phosphate and purine binding sites of the nucleotide binding pocket.  The backbone 
carbonyl of Gly14 in the P-loop (phosphate binding loop) sterically and electrostatically 
occludes the β-phosphate binding site.  The purine binding site of RhoA is altered by re-
orientation of Asn117 towards the purine.  However, the functional implication of the re-
arrangment of Asn117 is not clear because it seems to be favourably oriented to participate 
in a hydrogen bond with N7 of the purine.  A similar conformation of the residue 
equivalent to is observed in the Ras-SOS [2] and EF-Tu•EF-Ts [14] complex structure.  
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The collapse of Gly14 into the phosphate binding pocket is notable, because a 
similar collapse of the P-loop has only been observed in complexes with GEFs that do 
not contain a DH/PH module and directly contact the P-loop (i.e. EF-Ts-EF-Tu, SOS-
Ras, Sec7-Arf).  In contrast, Tiam, Dbs, and intersectin do not interact with the P-loop 
and in the structures of the DH/PH domains of these RhoGEFs with their respective 
GTPases the P-loop is intact and the β-phosphate binding site is coordinated with sulfate 
ions or highly ordered water molecules.  The intact P-loop in the RhoGEF structures 
could explain the about one to two orders of magnitude lower catalytic activities of 
RhoGEFs compared to other GEFs.  However, in the recent structure of Ran in complex 
with its GEF RCC1, the P-loop of Ran is also intact and stabilized by sulfate ions, even 
though there are direct contacts of the GEF with the P-loop.  This suggests that GEF 
catalyzed reactions generally proceed through the same structural changes independent of 
interactions of the GEF with the P-loop of the GTPase, and that the crystallization 
conditions might dictate if the GTPase is trapped with an intact or collapsed P-loop.  This 
is confirmed by the LARG-RhoA complex structure, where the P-loop is collapsed 
although there are no direct contacts between the GEF and the P-loop.  It was suggested 
that structures with an intact P-loop mimic a low-affinity ternary complex intermediate of 
GEF, GTPase and loosley bound nucleotide, whereas structures with a collapsed P-loop 
represent the high-affinity binary complex of GEF and GTPase [10, 11].  
The structural basis for the re-orientation of Gly14 and Asn117 in the complex with 
the LARG DH/PH domains is not clear, but it might be a result of the interaction of the 
N-terminal subdomain with switch I.  This interaction could stabilize the exposed 
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conformation of the nucleotide binding pocket.  Compared to other DH/PH-GTPase 
complexes this might not allow buffer ions to be trapped in the phosphate binding sites 
and the P-loop might therefore collapse into a conformation similar to the one seen in the 
LARG-RhoA complex.   
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3.3.7   An alternative conformation of RhoA 
 There are four unique DH/PH-RhoA complexes in the asymmetric unit of the 
DH/PH-RhoA crystals (complexes AB, CD, EF, GH).  In one of the complexes (AB), 
crystal contacts between RhoA-Asp165 and the α3 segment of a symmetry related AB 
complex have trapped RhoA in a dramatically different conformation.  Residues 160-164 
of RhoA, particularly Ala161, have collapsed into the purine-binding pocket (Fig. 3.22).  
An analogous collapse is observed in the Ras-Sos complex [2].  The side chain of RhoA-
Asp120, which in nucleotide-bound structures of RhoA forms hydrogen bonds with the N1 
and N2 nitrogens of guanine, is unchanged but instead supports the new conformation of 
this loop with two backbone hydrogen bonds.  While this conformation is caused by 
crystal contacts, it might represent an intermediary state of RhoA, after loss of 
magnesium and nucleotide.  It can be envisioned that this complex then relaxes into a 
conformation similar to those of the three other complexes in the asymmetric unit, where 
the nucleotide binding pocket is open and only the phosphate binding site is occluded.  
The nucleotide would then bind with the purine first and subsequently establish the 
contacts with the β- and γ-phosphates and ultimately lead to dissociation of the DH/PH 
domains from RhoA.  A similar sequence of nucleotide re-entry has been proposed for 
the SOS catalyzed nucleotide exchange on Ras [2].  However, for the RCC1 catalyzed 
exchange on Ran it has been proposed that the phosphate binds first and then the 
nucleotide based on the fact that the P-loop is intact [11].   
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3.3.8  PH domain-assisted nucleotide exchange in LARG 
Two contact regions between the LARG PH domain and RhoA could be 
responsible for PH-domain assisted nucleotide exchange in LARG.  The first is a direct 
contact between the N-terminus of the αC helix of the LARG PH domain and the Glu97 
side chain of RhoA.  Specifically, Glu97 of RhoA forms hydrogen bonds with the side 
chain and backbone amide of Ser1118 of LARG.  This interface buries about 200 Å2 of 
surface area.  The second region involves interactions between the DH domain and 
RhoA, which are supported by residues in the PH domain.  The end of α6 of the DH 
domain (residues 975 to 986), which constitutes the hinge between the DH and PH 
domains that moves upon RhoA binding, has several interactions with RhoA-Arg68 and 
these interactions are supported by residues from the β1 strand of the PH domain.  In 
particular, Glu982 and Asn983 of the α6 segment of LARG both coordinate the guanidino 
group of Arg68 of RhoA with a salt bridge and a hydrogen bond, respectively.  The side 
chain of Arg68 is also sandwiched between Arg986 and Lys979.  All of these α6 residues 
are supported by direct and specific contacts with the PH domain.  Asn983 is completely 
buried in the interface between the DH and PH domains and RhoA, and forms a hydrogen 
bond with the backbone carbonyl of Met1020 in β1 of the PH domain.  Lys979 likewise 
forms a hydrogen bond with the backbone carbonyl of Ile1021.  Arg986 is supported by a 
salt bridge with Glu1023 in β1.  Glu1023 also directly contacts Arg68 with a long-range salt 
bridge.  Glu980 of α6, and Lys1019 of β1, form yet another specific contact that helps to 
cement the interface between DH and PH domains.  These interdomain contacts are either 
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invariant or highly conserved among the Lbc family except for Glu1023, which is 
substituted with serine in intersectin and cysteine in Net1 and Xpln.   
The single direct contact between the PH domain and RhoA and the indirect 
contacts of the PH domain with RhoA at the DH-PH interface are reminiscent of what 
has been observed in the Dbs-Cdc42 [4] and Dbs-RhoA structures [3].  In both structures 
Dbs contacts the GTPase via a β3-β4 loop residue of the PH domain (Lys885).  However, 
mutation of contact residues on either the PH domain (Lys885) or Cdc42 (His103) did not 
influence exchange activity in vitro.  On the other hand, a triad of residues from the PH 
domain (Tyr889), the α6 segment of the DH domain (His814) and Cdc42 (Asp65) forms 
interactions, that seem to be important for nucleotide exchange, because a Y889F mutant 
has the most detrimental effect on nucleotide exchange.  The equivalent triad is not 
observed in LARG.  However, Lys979 of LARG is the equivalent residue to His814 in Dbs 
and when superimposed on RhoA, the Lys979-Ile1021 contact in LARG is in an equivalent 
position to the His814-Tyr889 contact in Dbs.  Furthermore, Glu1023 of the PH domain 
hydrogen bonds to residues in the DH domain (Arg986) as well as RhoA and might play 
an equally essential role to Tyr889 in Dbs.  
 
3.3.9  A protein docking site on the LARG PH domain 
In the DH/PH crystals, the PH domain forms a two-fold crystallographic dimer 
interface that buries 800 Å2 of surface area (Fig. 6).  The interface consists of a solvent-
exposed hydrophobic patch on the β4-β7 sheet of the PH domain, which includes the side 
chains of Leu1086, Ala1091, Phe1098, Ile1100, Ala1107, and Ile1109.  The hydrophobic patch of 
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all four of the PH domains in the asymmetric unit of the DH/PH-RhoA crystals form 
similar non-crystallographic dimer contacts.  Furthermore, all four of the PH domains in 
the DH/PH-RhoA crystal asymmetric unit are similarly dimerized with translationally-
related PH domains.  Although the PH domains in other DH/PH structures are also 
involved in crystal contacts, an equivalent hydrophobic patch is not observed in the Dbs, 
Tiam or intersectin DH/PH domains.  There is no evidence from size exclusion 
chromatography that the LARG DH/PH domains are dimeric in solution.  However, the 
residues that compose this solvent-exposed patch are highly conserved among the Lbc 
family of RhoGEFs, suggesting a conserved functional role for these solvent-exposed 
residues.  If the PH domain docks with the plasma membrane as it does in other well-
characterized PH domains (e.g. PLCδ1 [109]), this patch would be able to interact 
laterally with another peripheral membrane protein or another domain.  Based on these 
observations, the hydrophobic patch on the PH domain could represent a protein 
interaction site that could be exploited by either one of the other domains of LARG (e.g. 
PDZ or RH) or another protein (e.g. Gα13). 
 
3.3.10  Specificity of LARG for RhoA 
RhoGEFs exhibit a wide range of substrate specificities, from promiscuous 
RhoGEFs like Vav, which catalyzes nucleotide exchange on all three Rho subfamily 
proteins to strictly specific RhoGEFs like LARG, which catalyzes nucleotide exchange 
on RhoA only [54].  The structure of LARG is the first of a RhoA-selective RhoGEF and 
in comparison with previously determined DH/PH domains-GTPase complexes of Rac1-
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specific (Tiam), Cdc42-specific (intersectin) and Cdc42- and RhoA-specific (Dbs) GEFs, 
the structural basis of strict RhoA specificity can now be explained.   
In previously studied RhoGEFs, the regions of the DH domain most important for 
determining substrate specificity were proposed to be the α4-α5 loop, which interacts 
with residues of the β1 strand of the GTPase, and the N-terminal segment of the α5 helix, 
which accommodates Trp58 of RhoA (Trp56 in Rac1, Phe56 in Cdc42).  LARG indeed 
appears to use both of these regions to dictate specificity.  The side chain of Trp58 of 
RhoA is completely buried in the LARG interface and forms a hydrogen bond with the 
carboxylate of LARG-Asp928 (Fig. 3.23) a residue conserved as aspartate or glutamate 
among Lbc subfamily RhoGEFs except intersectin, which has a serine at the equivalent 
position.  Dbs, which is selective for either Cdc42 or RhoA, also has a serine (Ser763) in 
this position, and accommodates either Trp58 of RhoA or the equivalent Phe56 of Cdc42 
in part by altering the side chain conformation of Ser763 as well as of Leu766.  The 
equivalent residue to Dbs-Leu766 is LARG-Pro931, whose side chain is relatively short and 
rigid.  Therefore, the binding of Cdc42 to LARG is disfavored in part because its Phe56 
residue would clash with the LARG-Asp928 side chain and leave a cavity in the interface 
next to LARG-Pro931.  However, LARG-Pro931 is not conserved throughout the RhoA-
specific Lbc family RhoGEFs, but is a leucine in most members of this family.  It can 
therefore not solely be responsible for RhoA specificity.  
Although the region in the α5 helix, that accommodates Trp58/Phe56 seems to play 
an essential role in the discrimination between RhoA and Cdc42, or Rac1 and Cdc42, it 
does not explain the discrimination between RhoA and Rac1, which both have a 
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tryptophan in this position.  The second proposed specificity-determining contact region 
in the α4-α5 loop of the DH domain therefore has to be considered.  The α4-α5 loop 
makes contacts to the β2-β3 sheet of the GTPase as well as to the N-terminal region of 
the GTPase.  Arg923 in the α4-α5 loop of LARG forms salt-bridges with both Asp45 and 
Glu54 of the β2-β3 sheet of RhoA, which are substituted by shorter polar side chains in 
Rac1 and Cdc42 (Asn43, Thr52).  Arg923 is invariant throughout the Lbc subfamily of 
RhoGEFs except intersectin, whose equivalent residue is glycine.  Intersectin is the only 
Lbc subfamily RhoGEF that catalyzes nucleotide exchange on Cdc42 and not RhoA.  The 
equivalent residue to LARG-Arg923 in Dbs is Lys758, which has a hydrogen bond to 
RhoA-Glu54 in the Dbs-RhoA structure but no interactions with this region in the Dbs-
Cdc42 structure.  In Tiam, which is specific for Rac1, the equivalent residue is Gln1177, 
which also does not interact with the β2-β3 sheet in Rac1.  It therefore seems that 
contacts to the β2-β3 sheet are relevant for the specific recognition of RhoA, but do not 
play a role in the recognition of Cdc42 and Rac1.  Contacts between the α4-α5 loop of 
the LARG DH domain and the N-terminal region of the GTPase also seem to be essential 
in the discrimination between RhoA and Rac1.  Arg5 packs against the α4-α5 loop and 
forms a hydrogen bond with the Arg923 backbone carbonyl.  Arg5 is substituted with an 
alanine in Rac1.   
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Figure 3.23: Contacts between the LARG DH/PH domains and RhoA expected to 
dictate substrate specificity.  (a) As predicted in prior studies [3], Arg923 in the α4-α5 
loop of LARG makes multiple salt bridge interactions with an acidic patch on the surface 
of RhoA that consists of Asp45 and Glu54 (substituted by asparagine and threonine, 
respectively, in both Rac and Cdc42).  Arg5 of RhoA (substituted by alanine and 
threonine in Rac and Cdc42, respectively) packs against the α4-α5 loop of LARG and 
forms a hydrogen bond with the backbone carbonyl of Arg923.  Adjacent to Arg5, a salt 
bridge is formed between LARG-Lys899 and RhoA-Asp76 (not shown).  Asp76 is 
substituted by a glutamine in both Rac1 and Cdc42, and therefore this contact could also 
contribute to substrate specificity.  The mesh cage represents a σA-weighted 2|Fo|-|Fc| 
Fourier map contoured at 1.0 σ, generated using the CCP4 program suite.  (b) The same 
interface rotated 90˚ around a vertical axis, highlighting interactions with RhoA-Trp58, 
which is completely buried at the interface.  Asp928 of LARG, which is conserved as an 
acidic residue in all Lbc subfamily RhoGEFs except for intersectin, forms hydrogen 
bonds that bridge Trp58 of RhoA and a backbone nitrogen in the LARG α4-α5 loop.  In 
Cdc42, Trp58 is substituted by phenylalanine, which would be incompatible with Asp928 
of LARG and leave a cavity in the interface.  Val43 of RhoA (substituted by serine and 
alanine in Rac and Cdc42, respectively) packs snuggly against the side chain of LARG-
Arg923.  Conservative substitution of this valine residue with isoleucine, as in RhoC, 
could not be easily accommodated.  Indeed, it was recently reported that Xpln, another 
Lbc subfamily RhoGEF selective for RhoA, can catalyze nucleotide exchange on RhoA 




4.  Kinetic assessment of LARG fragments and mutants by fluorescence 
spectroscopy 
4.1  Introduction 
In order to confirm the functionality of the crystallized DH/PH domains, and to 
assess mutants, that were generated, based on the structural analysis, as well as various 
LARG fragments, a fluorescence assay was developed.  Unlike Ras, Rho GTPases have a 
tryptophan in proximity to the nucleotide-binding site (Trp99 in RhoA).  Therefore, 
various approaches can be taken to the kinetic assessment of RhoGEFs (Fig. 4.1).  
Previous fluorescence assays of DH/PH domains measured either fluorescence from the 
nucleotide-sensitive tryptophan (Fig. 4.1a) or from a fluorescent nucleotide 
(methylanthraniloyl (mant)-GTP or mant-GDP) (Figure 4.1b, c).  For Ras and Ran it has 
been shown that mant-nucleotides bind with similar affinity compared to un-modified 
nucleotides and that the on and off rates are comparable [114, 116, 117]. 
Here, an assay was developed that records the decrease of fluorescence 
resonance energy transfer (FRET) from Trp99 in RhoA to mant-GDP upon its exchange 
for GTP (Figure 4.1d).  This assay was developed with the intention of getting an 
improved signal to noise ratio.  The assay was successfully used to assess the relative 
activities of various LARG fragments as well as of DH/PH domains mutants and RhoA 
mutants.  Preliminary data for the determination of Michaelis-Menten parameters were 




Figure 4.1:  Various approaches for the assessment of the catalytic rates of 
RhoGEFs.  (a) The decrease in tryptophan fluorescence upon exchange of GDP for a 
fluorescent nucleotide (methylanthraniloyl (mant) GTP) can be measured [4].  (b) The 
increase in fluorescence upon exchange of GDP for either mant-GTP or mant-GDP can 
be measured [3, 5].  (c) The decrease in fluorescence upon exchange of mant-GDP for 
GDP can be measured [7].  (d) The decrease in FRET upon exchange of GTP for mant-
GDP has been measured in this study.  
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4.2  Methods  
4.2.1  Cloning and Purification of proteins used in the fluorescence assays 
A fragment of human LARG encoding the RH/DH/PH domains (residues 341 to 
1138) was inserted into the pMALc2T-H6 vector (see 3.2.1) using BamH I and Sal I 
restriction sites and purified as described for the DH/PH domains (see 3.2.1, Fig 4.2).  
Fragments encoding the LARG DH domain (residues 765 to 986) and RH/DH domains 
(residues 341 to 986) were cloned into the pMALc2H10T vector (see 3.2.3) using BamH I 
and Sal I restriction sites and purified as described for RhoA (see 3.2.3, Figs 4.3, 4.4,), 
substituting buffers used for RhoA purification with buffers used for DH/PH domains 
purification.  The yield for the RH/DH and RH/DH/PH fragments was 5 mgl/liter cell 
cultures.  The yield for the DH domain was 15 mg/liter of cell culture.    
Human Rac1 and Cdc42 were cloned from pCDNA3 vectors (a gift from Dr. S. 
Dharmawardhane) into the pMALc2H10T plasmid and purified as described for RhoA 
(see 3.2.3).   
DH/PH and RhoA mutants were generated by site directed mutagenesis using the 
Quickchange site directed mutagenesis kit (Stratagene) and purified as described for the 
wild type proteins (see 3.2.1, 3.2.3) [92]. 
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Figure 4.2: Purification of the LARG RH/DH domains.  The LARG RH/DH domains 
were expressed from a modified pMAL vector as an N-terminal fusion protein with MBP 
and a C-terminal H6 tag.  The MBP-RH/DH-H6 fusion protein was purified on a NiNTA 
column, digetsted with TEV protease, and the RH/DH-H6 domains were separated from 
MBP by another NiNTA column.  Subsequently the RH/DH-H6 domains were purified 
on a gel filtration column (S200, 16/60, Amersham Pharmacia).  The RH/DH-H6 domains 
eluted at a flow rate of 1ml/min.  Fractions 66-78 were pooled and concentrated to about 
10 mg/ml.   
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Figure 4.3:  Purification of the LARG RH/DH/PH domains.  The LARG 
RH/DH/PHdomains were expressed from a modified pMAL vector as an N-terminal 
fusion protein with MBP and a C-terminal H6 tag.  The MBP-RH/DH/PH-H6 fusion 
protein was purified on a NiNTA column, digetsted with TEV protease, and the 
RH/DH/PH-H6 domains were separated from MBP by another NiNTA column.  
Subsequently the RH/DH/PH-H6 domains were purified on a gel filtration column (S200, 
16/60, Amersham Pharmacia).  The RH/DH/PH-H6 domains eluted at a flow rate of 







4.2.2  Fluorescence Assays  
As shown in figure 4.1d GTPases were pre-loaded with mant-GDP and the 
exchange reaction was performed in the presence of the GEF and an excess of GTP.  
Nucleotide exchange was measured at an excitation wavelength of 280 nm and emission 
wavelength of 430 nm.  At 280 nm a tryptophan (Trp99) close to the nucleotide binding 
pocket is excited and loss of FRET from Trp99 to the mant group of mant-GDP is 
measured upon exchange of mant-GDP for GTP.  
  
Loading of Rho GTPases with mant-GDP:  GTPases were loaded with mant-
GDP by incubating 100 to 200 µl of a 180 µM GTPase in loading buffer (20 mM HEPES 
pH 8.0, 100 mM NaCl, 4 mM EDTA, 1 mM DTT) for 1.5 hrs on ice with a ten fold molar 
excess of mant-GDP (Jena Bioscience).  Subsequently, mant-GDP loaded GTPases were 
stabilized by addition of MgCl2 to a final concentration of 10 mM and incubation for an 
additional 30 min on ice.  EDTA and free nucleotide were removed by exchanging mant-
GDP loaded GTPases into reaction buffer (20 mM HEPES pH 8.0, 150 mM NaCl, 
10 mM MgCl2, 1 mM DTT) via gel filtration on a Sephadex G-10 (Sigma) column of 
approximately 3 ml bed volume.  The gel filtration column was pre-equilibrated with 
reaction buffer.  Mant-GDP loaded GTPase was eluted in approximately 100 µl fractions, 
and the protein content of the fractions was assessed by mixing 3 to 6 µl of the eluted 
fractions with 50 µl of Bradford solution.  Mant-GDP loaded GTPases eluted between 
fractions 11 to 17.  These fractions were pooled and the concentration of mant-GDP-
RhoA was determined by absorption readings at 280 nm and at 360 nm, which is the 
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excitation maximum of mant-GDP.  The extinction coefficient of mant-GDP is 5700 M-1 
cm-1.  The ratio between concentrations determined at 360 nm and 280 nm gives an 
estimate of the ratio of mant-GDP loaded RhoA to total RhoA (loaded and unloaded 
RhoA).  According to this estimation 50-90% loading was achieved using this method.  
Loading of Rac1 with mant-GDP was verified with the N-terminal DH/PH domains of 
Trio (a gift from Dr. Nicolas Nassar, Stony Brook University), that specifically 
exchanges nucleotides on Rac1 and RhoG, but not Cdc42 or RhoA [118, 119].  
 
Nucleotide exchange assays:  Exchange assays were performed on a FluoroMax-3 
spectrofluorometer at 25° C, in a 200 µl cuvette (λex = 280 nm, λem = 430 nm, 
slits = 2/2 nm).  Ten µl of 2 mM GTP (final GTP concentration is 100  µM) were added 
to 180 µl of 1.1 µM mant-GDP loaded GTPases (final GTPase concentration is 1.0  µM) 
and the solution was subjected to two pulses of vortexing.  The exchange reaction was 
started with the addition of 10 µl of a 2 µM GEF solution (final GEF concentration is 100 
nM) and traces were recorded after two pulses of vortexing.  Mant-GDP loaded GTPase 
was kept at 25° C, GTP and GEF solutions were kept on ice.  Reactions were traced for 
300 to 500 sec.  The baseline of the uncatalyzed nucleotide exchange was traced for 1000 
sec.  Reactions were performed at least in triplicate.  
 
Data assessment:  kobs were determined by fitting the traces to an equation describing 
a one-phase exponential decay using the program Graphpad Prism version 4.0.  To obtain 
a better fit for the very flat traces of the uncatalyzed exchange the value for the total 
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fluorescence change (equivalent to the PLATEAU in the program Prism) was fixed to a 
value that corresonds to the total fluorescence change for the DH/PH domains catalyzed 
reaction. 
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4.3  Results and discussion 
4.3.1  FRET versus mant-nucleotide and tryptophan fluorescence 
Previous kinetic studies of RhoGEF DH/PH domains and their mutants were 
performed by either measuring changes in tryptophan fluorescence or mant-nucleotide 
fluorescence upon nucleotide exchange (Fig. 4.1a-c) [4, 5, 7].  Here we developed a 
FRET-based assay to increase the signal to noise ratio and to decrease the necessary 
amount of mant-nucleotide used (Fig. 4.1d).  Although one of the previously used assays 
is based on the decrease of tryptophan fluorescence due to binding of and energy transfter 
to mant-nucleotide (Fig. 4.1a) [4], our assay would be expected to result in a higher 
signal to noise ratio because there is a larger difference between the excitation and 
emission wavelengths (Fig. 1.4).  Indeed, only a two fold increase in signal to noise ratio 
was reported for Rap2A when the decrease of tryptophan fluorescence was measured 
[120].  In our assay, however, a 10 fold increase of the signal to noise ratio was observed, 
with FRET as opposed to mant-fluorescence, as determined by the maximal achievable 
fluorescence change of the GEF catalyzed reaction.  Furthermore, a second tryptophan in 
RhoA (Trp58) is intimately involved in the association with the DH domain and could 
contribute to the measured fluorescence changes of an exchange reaction.  This 
contribution would shift the detected rates towards rates of binding rather than rates of 
nucleotide exchange.  By measuring FRET these effects should be diminished because 
Trp58 is about 4 Å further away from the nucleotide than Trp99 and energy transfer 
decreases with the distance to the sixth power (r6).  Besides improving the signal to noise 
ratio, the assay developed here also reduces the amount of fluorescent nucleotide used in 
127 
the reaction mix, which is not only more economical but also decreases the possibility of 
internal fluorescence effects, due to the mant-nucleotide.  At high concentrations of mant-
nucleotide the fluorescence from the mant-group could be quenched by the nucleotide.  
 
4.3.2  Fluorescence assays of DH/PH and RhoA mutants 
Based on the structural analysis of the LARG DH/PH domains in complex with 
RhoA, mutants of the DH/PH domains and RhoA were designed to better understand the 
role of the unusual N-terminal subdomain of the LARG DH domain and the functional 
basis for PH domain-assisted nucleotide exchange in LARG.  The following hypotheses 
were tested:  
Hypothesis 1: The N-terminal extension is involved in nucleotide exchange.  This 
might be due to interactions with switch I, which leave the nucleotide binding site more 
exposed and stabilize nucleotide-free RhoA.  Deleting or disturbing the structural 
integrity of the N-terminal subdomain will result in decreased nucleotide exchange rates.  
Mutants that were generated to test this hypothesis are: ∆N-DHPH, DHPH-769A, DHPH-
769D, DHPH-790G, ∆N-DHPH/790G, RhoA-33E, RhoA-27T. 
Hypothesis 2: The N-terminal extension is a specificity-determining region for 
RhoA selective RhoGEFs.  N-terminal deletion mutants will catalyze nucleotide 
exchange on Cdc42 and/or Rac1.   
Hypothesis 3: PH domain-assisted nucleotide exchange in LARG is based on 
either the direct interaction of LARG-Ser1118 with RhoA-Glu97 and/or LARG-Glu1023 with 
RhoA-Arg68.  Allternatively, LARG-Glu1023 could indirectly act on RhoA by supporting 
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an interaction of the DH domain with RhoA (LARG-Arg986-RhoA-Arg68).  Point 
mutations in this region on RhoA or the PH domain will therefore result in nucleotide 
exchange rates that are comparable to the DH domain alone.  Mutants that were 
generated to test this hypothesis are: RhoA-97A, DHPH-1023A, DHPH-1023R.  
 
Role of the N-terminal subdomain in nucleotide exchange – Hypothesis 1 
 Structural analysis of the DH/PH domains in complex with RhoA suggests a role 
for the N-terminal subdomain in RhoA binding and nucleotide exchange.  The 
contribution of the N-terminal extension to nucleotide exchange activity was therefore 
investigated by assaying an N-terminal deletion mutant (∆N-DHPH) as well as mutants 
that would be expected to exhibit problems with the structural integrity of the N-terminal 
subdomain (DHPH-769A, DHPH-769D, DHPH-790G).  Furthermore, the residues in 
RhoA, that interact with the N-terminal subdomain have been mutated (RhoA 27T, RhoA 
33E).   
The Trp769 mutants reduced nucleotide exchange activity to about the same level 
as the N-terminal deletion mutant (13-20% of the wild type DH/PH domains, Fig 4.2).  
This suggests that Trp769 is important for the structural integrity of the N-terminal 
subdomain.  The DHPH-790G mutant also reduced the catalytic activity (about 25% of 
wild type DH/PH, Fig 4.2), suggesting that this residue also contributes to the structural 
integrity of the subdomain.  This result could also indicate that the substitution of Glu790 
for glycine in intersectin, would not support an equivalent N-terminal subdomain.  
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Surprisingly, the RhoA 27T and RhoA 33E mutants were not compromised in 
their nucleotide exchange activities (Table 4.1).  These results could be explained by the 
fact that the electron density for the RhoA-Lys27 side chain is weak, and this residue is 
perhaps unimportant for binding LARG.  Val33 is partially solvent exposed, and 
substitution by a bulkier side chain could therefore be accommodated without 
compromising binding.   
An interesting observation is that the Val33 mutant partially rescued the activity of 
the N-terminal deletion mutant (Fig 4.2).  The reason for this observation is unclear.  It 
might be possible that a residue in the α1 helix is re-oriented upon deletion of the N-
terminus and favorably interacts with Glu33.  The only residue that could possibly be 
involved is Lys787.  However, it seems structurally very unlikely.  
Given that the RhoA-33E mutation has no effect on nucleotide exchange, it is 
somewhat surprising that the DHPH-769A, DHPH-769D and ∆N-DHPH mutations of 
LARG had such a dramatic effect on activity.  One explanation could be indirect effects 
on the conformation of Glu790 of LARG, whose side chain is constrained via three 
hydrogen bonds with the N-terminal subdomain, two to backbone amides and one to the 
side chain of Gln770.  Upon binding RhoA, the side chain of Glu790 is completely buried 
in the RhoA interface and packs against the side chain of Tyr34 in the RhoA effector loop.  
Therefore, destabilization of the N-terminal subdomain by point mutation of its core 
hydrophobic residue, or its complete removal, could lead to release of the Glu790 side 
chain, allowing it to assume a more extended conformation that interferes with RhoA 
binding.  To test this hypothesis, we constructed a ∆N-DHPH/790G mutation of the 
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LARG DH/PH domain.  However, this double mutant did not rescue the activity of the 
∆N-DHPH mutant.  The role of the N-terminal subdomain in nucleotide exchange on 
RhoA is therefore not dependent on its ability to sequester an extended conformation of 
Glu790.  The results from the Glu790 mutants show that this residue is indispensable for 
nucleotide exchange and suggest that its interface with Tyr34 of switch I is a critical 
interaction.   
Although the reduced catalytic activity of the DH/PH mutants could also be due 
to a population of molecules that are in an unfolded or not properly folded state, they 
correspond to activities of mutants of the Dbs DH/PH domains, which were reduced to 
about 10-16% [4, 121].  For one of the Dbs mutants (Y889F) a crystal structure was 





Figure 4.4:  The N-terminal subdomain of the LARG DH/PH domains plays an 
essential role in nucleotide exchange.  Nucleotide exchange on RhoA was measured 
using a FRET-based nucleotide exchange assay.  For each time course, 1 µM of mant-
GDP loaded RhoA was incubated with 100 µM GTP at 25 °C, and the exchange reaction 
was started by the addition of 100 nM LARG fragments or mutants, except for the 
baseline.  The subsequent decrease in fluorescence (λex=280 nm, λem=430 nm) was then 
measured for 300 sec.  Each curve shown is the average of 2-3 measurements.  Traces of 
baseline nucleotide exchange of the RhoA-33E mutant and traces of DH/PH domains 
catalyzed nucleotide on RhoA-33E are as for the RhoAwt and are not shown.  The W769, 
E790, and the N-terminal deletion mutants are all predicted to interfere with the structural 




 Rate of Nucleotide Exchange (s-1x10-3) ‡ 
LARG Fragment RhoA RhoA-V33E RhoA-K27T RhoA-E97A 
None 0.15 ± 0.007 0.13 ± 0.007 ND ND 
DH (765-986) 3.7 ± 0.25 (25)† ND|| ND ND 
DHPH (765-1138) 5.0 ± 0.25 (33) 5.5 ± 0.06 (42) 5.1 ± 0.84 5.6 ± 0.29 
DHPH-∆N 1.0 ± 0.07 (6.6) 1.9 ± 0.06 (15) ND ND 
DHPH-W769A 0.75 ± 0.02 (5) 1.1 ± 0.07 (8.5) ND ND 
DHPH-W769D 0.68 ± 0.02 (4.5) 1.0 ± 0.04 (7.7) ND ND 
DHPH-E1023A 3.6 ± 0.1 (24) ND ND ND 
DHPH-E1023R 2.2 ± 0.04 (15) ND ND ND 
DHPH-E790G 1.3 ± 0.06 (8.6) ND ND ND 
DHPH-E790G/∆N 1.2  ± 0.02 (8) ND ND ND 
RHDH (341-986) 1.49 ± 0.13 (12.1) ND ND ND 
RHDHPH (341-1138) 1.42 ± 0.11 (10.7) ND ND ND 
‡To calculate kobs, each curve was fit to a single-order exponential decay with Prism v 4.0.  Each data point 
is the average of at least three measurements.† 
\Numbers in parentheses correspond to the fold rate enhancement over the basal rate in the absence of 
LARG, if measured.  
||ND: not determined. 
 
Table 4.1:  Summary of kobs from wild-type and mutant LARG and RhoA proteins.  
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Role of the N-terminal subdomain in specific nucleotide exchange on RhoA – 
Hypothesis 2 
Sequence comparison suggests that the N-terminal extension might play a role in 
specific recognition of RhoA, because amino acids that comprise the hydrophobic core of 
the N-terminal subdomain are only conserved throughout the Lbc family of RhoA 
specific Rho GEFs.  The only exception is intersectin, which is the only family member 
that is specific for Cdc42.  In support of this hypothesis, an interesting observation was 
made when an LARG DH/PH domain construct (residues 785-1140), that lacked the N-
terminal extension, was studied [54].  This construct showed some nucleotide exchange 
on Cdc42.  We therefore tested the ∆N-DHPH mutant (residues 782-1138) and the ∆N-
DHPH/790G double mutant against Cdc42 and Rac1.  The ∆N-DHPH/790G mutant was 
investigated to rule out the possiblility that a lack of activity it is not the result of 
interference of Glu790 with Cdc42 and/or Rac1 binding.  However, both mutants did not 
show any exchange activity on Cdc42 and Rac1 (data not shown).  
 
PH domain-assisted nucleotide exchange in LARG – Hypothesis 3 
 The invariant presence of a PH domain C-terminal to the DH domain in RhoGEFs 
suggests a direct role of the PH domain in catalysis.  Indeed, increased in vitro exchange 
activities of DH/PH vs. DH domains have been reported for Dbs (26 fold) [4], Trio (2 
fold) [122], and a fragment of the LARG DH/PH domains (residues 785-1140), that does 
not contain the N-terminal extension (values of the fold enhancement were not calculated 
for this protein) [54].  Consistent with these studies, the fragment of the LARG DH/PH 
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domains (residues 765-1138) that was used in crystallization showed about 2 fold higher 
activity than the DH domain.  The fact that the Dbs and Trio DH domains are so much 
more compromised in their activities than the LARG DH domain compared to their 
respective DH/PH domains indicates that the PH domains of these proteins have stronger 
or more interactions with their GTPases.  The β3-β4 loop of the Dbs PH domain indeed 
has extensive contacts with the switch II region of the GTPase and with the C-terminus of 
the α5 helix of the GTPase [4].  However, both interaction regions do not seem to be 
important for PH domain-assisted nucleotide exchange in vitro.  An alternative 
explanation for the less compromised activity of the LARG DH domain compared to the 
DH/PH domains could be that the N-terminal subdomain of LARG contributes 
considerably to the binding of RhoA.  
The only case where the basis of PH domain-assisted nucleotide exchange in a 
RhoGEF is well understood is in Dbs, where residues of the PH domain, that support 
interactions of the DH domain with the GTPase seem to be essential for catalysis (see 
3.3.7) [4].  The LARG DH/PH-RhoA complex structure suggests a similar basis for PH 
domain-assisted nucleotide exchange.  Therefore, the contribution of the contact of 
Glu1023 with RhoA (Arg68) and the DH domain (Arg986) was analyzed by site directed 
mutagenesis.  Furthermore, the direct contact between Ser1118 and Glu97 was analyzed by 
investigating a RhoA-97A mutant.  Nucleotide exchange of RhoA-97A was nearly 
identical to that of wild-type RhoA (data not shown), suggesting, that this small, 
unconserved yet direct interface between the PH domain of LARG and RhoA is not 
important for nucleotide exchange, at least in vitro.  This notion is supported by the fact 
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that Ser1118 and adjacent residues are not conserved among either the Lbc subfamily or 
RH-RhoGEFs.  A smilar, but even more surprising obervation was made in Dbs, where 
mutating both the Cdc42 (Arg66) and the PH domain contact residue (Tyr889), revealed 
that the Y889F mutant severely diminished nucleotide exchange activity even though the 
R66A mutant had the same activity as wild type RhoA [4].  Because Tyr889 supports 
contacts of the DH domain with Cdc42 (His814-Cdc42-Arg66), this result could suggest 
that, although the hinge region of the DH/PH domains can accommodate different side 
chains within the contact region on the GTPase, the full catalytic activity is dependent on 
the structural integrity of the DH/PH interface.  However, the structure of the Dbs-Y889F 
mutant in complex with Cdc42 has been solved and the relative disposition of PH to DH 
domains is unchanged compared to wtDbs.  Dbs catalyzed nucleotide exchanges in Dbs 
has been shown to be dependent on the interaction of Dbs-His814 with Cdc42-Asp65, 
because mutations in either residue severly diminishes exchange activity.  It was 
therefore suggested that Tyr899 stabilizes the electronic configuration of His814 to promote 
interaction with Asp65 in Cdc42.   
The lack of an effect of the RhoA97A mutant in LARG catalysis in vitro does not 
rule out the possibility that this direct interaction between the LARG PH domain and 
RhoA is used for PH domain-assisted nucleotide exchange in vivo.  For example, the 
mutation of a residue in the Dbs PH domain that directly contacts the GTPase (Lys885), 
did not compromise activity in vitro [4].  However, in in vivo focus formation assays, this 
contact was also shown to be important [88].  These results suggest that in vivo the 
RhoGEF could be regulated through interactions of its PH domain with other 
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intramolecular domains (e.g. PDZ, RH domains) or other proteins (e.g. Gα13, actin) or 
through interactions with membranes.  In vivo PH domains might be positioned more 
optimally with respect to their adjacent DH domains and their respective GTPases, and 
disruption of this positioning in vivo might result in a more pronounced effect than in 
vitro.  In in vitro assays however, the basal GEF activity might already be severly 
compromised compared to in vivo activities and mutations in the PH domain-RhoA 
interface will not be detected. 
On the other hand, the E1023A mutant of LARG demonstrates diminished GEF 
activity towards RhoA to about the same extent as the DH domain alone (Fig 4.3).  The 
E1023R mutation, which introduces electrostatic repulsion as well as potential steric 
clashes, is even less active.  These results verify the importance of interactions between 
the DH and PH domains of LARG at the hinge region, and based on similarities with 
Dbs, suggest a general mechanism by which PH domains can assist nucleotide exchange 
in RhoGEFs.  
137 
 
Figure 4.5:  Mutation of Glu1023 eliminates PH domain-assisted nucleotide exchange 
in LARG.  Nucleotide exchange on RhoA was measured using a FRET-based nucleotide 
exchange assay.  For each time course, 1 µM of mant-GDP loaded RhoA was incubated 
with 100 µM GTP at 25 °C, and the exchange reaction was started by the addition of 100 
nM LARG fragments or mutants, except for the baseline.  The subsequent decrease in 
fluorescence (λex=280 nm, λem=430 nm) was then measured for 300 sec.  Each curve 
shown is the average of 2-3 measurements.  Glu1023 has direct contacts to RhoA via a 
long-range salt bridge to Arg68 and indirect contacts via Arg986 in the DH domain.  
Mutations of Glu1023 reduce the activity of the DHPH domains to a level that is similar to 
the DH domain activity alone. 
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4.3.3  Fluorescence assays of LARG fragments containing the RH domain 
A comparison of LARG constructs containing the RH domain with constructs 
without the RH domain shows an inhibitory role of the RH domain in vitro.  This is 
consistent with initial data reported on p115RhoGEF catalyzed exchange on un-
prenylated RhoA [56], that showed increased activity when the RH domain was truncated 
and would support an auto-inhibitory model for the effect of the LARG RH domain.  
However, when prenylated RhoA was used in the p115RhoGEF assays, a construct that 
lacked the RH domain showed decreased activity [57, 58].  Because data from assays 
with prenylated RhoA are not available for LARG, it can only be assumed from the close 
sequence homology between p115RhoGEF and LARG that the LARG RH domain also 
contributes to nucleotide exchange in vivo.  However, there are differences in the 
p115RhoGEF constructs compared to the LARG constructs, which make it hard to apply 
conclusions from the p115RhoGEF assays to LARG.  The p115RhoGEF DHPH construct 
contained approximately 100 amino acids N-terminal to the DH domain, which could 
affect the exchange rates.  Furthermore, the results from our flourescence assays could, 
indeed represent the in vivo activity of the RH domain containing LARG fragments, if the 
presence of the PDZ domain in LARG results in a different domain architecture 
compared to p115RhoGEF, which does not have a PDZ domain.  
It is curious that the LARG PH domain does not contribute to the exchange 
activity when the RH domain is present, instead the RHDHPH and RHDH constructs 
have comparable activities.  This could mean that the RH domain associates with the 
DH/PH domains in a way that prevents the PH domain from assuming a favorable 
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relative position to the DH domain.  These results are in contrast to the p115RhoGEF 
constructs where the PH domain also enhances nucleotide exchange in a construct that 
contains the RH domain (5 fold higher activity of RHDHPH compared to RHDH).  
However, in p115RhoGEF the DHPH construct has an about 14 fold higher activity 
compared to the DH construct.  The RH domain of p115RhoGEF therefore also seems to 
diminish the effect of the PH domain on nucleotide exchange.   
The fact that the N-terminal LARG mutants show approximately the same activity 
as the RH domain containing constructs might be an indication that the RH domain 
interacts with the N-terminal subdomain and effectively keeps it from eliciting its 
supporting role and therefore keeps DH/PH domains in a less active state.  LARG 
activation by Gα12/13 binding to the RH domain could change the conformation and 




Figure 4.6:  LARG constructs including the RH domain have diminished 
nucleotide exchange activity in vitro.  Nucleotide exchange on RhoA was measured 
using a FRET-based nucleotide exchange assay.  For each time course, 1 µM of mant-
GDP loaded RhoA was incubated with 100 µM GTP at 25 °C, and the exchange reaction 
was started by the addition of 100 nM LARG fragments or mutants, except for the 
baseline.  The subsequent decrease in fluorescence (λex=280 nm, λem=430 nm) was then 
measured for 300 sec.  Each curve shown is the average of 2-3 measurements.  The fact 
that the N-terminal LARG mutants show approximately the same activity as the RH 
domain containing constructs might be an indication that the RH domain interacts with 
the N-terminal subdomain and effectively keeps it from eliciting its supporting role and 
therefore keeps DH/PH domains in a less active state.  LARG activation by Gα12/13 
binding to the RH domain could change the conformation and release the N-terminus into 
a conformation that leads to full activity. 
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4.4  Preliminary determination of Michaelis-Menten parameters 
 Attempts were made to determine Michaelis-Menten parameters.  Michaelis-
Menten kinetics are considered steady state kinetics, following a scheme shown in 
Figure 4.  The ‘steady state’ in Michaelis-Menten measurements refers to a condition 
where the concentration of the enzyme-substrate complex ([ES]) does not significantly 
change.  Michaelis-Menten kinetics work under several assumptions.  (1) The enzyme-
substrate complex is in equilibrium with free enzyme and free substrate and therefore k2 
is much smaller than k-1.  (2) The enzyme is present in limiting concentrations relative to 
the substrate and all enzyme is present in a complex with the substrate.  (3) The substrate 
concentration is much higher than the enzyme concentration and therefore does not 
significantly change during the enzyme-catalyzed reaction.  Assuming Michaelis-Menten 
conditions KM can be equated with KD and an increase in KM could therefore be an 
indication for impeded substrate binding.  Changes in Vmax on the other hand suggest 
changes at the catalytic site.   
 
Figure 4.7: Summary of the assumptions in Michalis-Menten-type kinetics.  
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4.4.1  Methods 
30 nM DH/PH domains were incubated with 0.5-4 µM mant-GDP loaded RhoA 
and the initial velocity was determined by fitting a line to the first 100 sec.  An average of 
at least two measurements is reported.  The initial velocity was plotted against the RhoA 




4.4.2  Results and Discussion 
 The kcat for the LARG DH/PH domains is comparable to kcat values reported for 
the catalytic domain of SopE, a RhoGEF from Salmonella enterica, as well as the Dbl 
family RhoGEFs Dbl, and Lfc (Table 4.2).  The increased KM of the LARG DH/PH 
domains may be a result of the fact that KM for Dbl and Lbc were determined with full 
length proteins and additional domains in these RhoGEFs might contribute to binding of 
the GTPase.  The preliminary data for LARG are indicating that the developed FRET 
assay can be used for the determination of Michaelis-Menten parameters.  However, the 
results have to be interpreted carefully because initial velocities were only determined 
over a small substrate concentration range.  Furthermore, the RHDH and RHDHPH 
constructs were partially degraded during purification (Fig. 4.2 and 4.3) and the 
diminished GEF activities of these constructs could therefore be a result of a smaller 
fraction of active protein.  Although activities of various RhoGEF DH/PH domains have 
been assessed in vitro using fluorescence and filter binding assays, Michaelis-Menten 
parameters have not been determined for most RhoGEFs.  It is therefore impossible to 
compare the activity of the LARG DH/PH domains to activities that have been reported 
for other DH/PH domains of known structure.  This would be interesting, because 
differences in kcat and KM could indicate if the N-terminal subdomain of the LARG 




Figure 4.8:  Preliminary Michalis-Menten plot for the LARG DH/PH domains. 30 
nM DH/PH domains were incubated with 0.5-4 µM mant-GDP loaded RhoA and the 
initial velocity was determined by fitting a line to the first 100 sec.  An average of at least 
two measurements is reported.  The initial velocity was plotted against the RhoA 
concentration and a hyperbola was fit to the curve using the program Graphpad Prism 
version 4.0.  The Michaelis-Menten parameters are comparable to the ones reported for 
other RhoGEFs (see Table 4.2).   
 
 KM (µM) kcat (sec
-1) 
LARG (DH/PH) 11.92 ± 1.8 1.01 ± 0.004 
Dbl (full length) [123] 0.151 ± 0.003 1.98 ± 0.10 
Lbc (full length) [123] 0.177 ± 0.03 1.16 ± 0.3 
SopE (catalytic domain) 
[124] 
1.7 ± 0.8 1.1 ± 0.1 
 
Table 4.2: Michaelis-Menten paramters of the LARG DH/PH domains in 
comparison to other RhoGEFs.  
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4.5  Technical problems with the fluorescence assays 
Inconsistency of A280 readings compared to Bradford and BCA 
Absorption readings at 280 nm consistently yielded lower concentrations for the 
DH domain and higher concentrations for the RHDHPH domains compared to the 
Bradford and bicinchoninic acid (BCA) methods.  Concentrations were the same for the 
DHPH and RHDH domains.  Protein concentrations for the determination of exchange 
rates were determined by the Bradford method.  Protein concentrations for the assessment 
of Michaelis-Menten parameters were determined by absorption readings at 280 nm.  The 
concentration of the DH domain, determined by absorption was consistently about half as 
much as when determined by the Bradford method.   Although the DH domain 
concentration in these assays might therefore have been about twice as high, i.e. 10 nM 
instead of 5 nM, concentrations of the DHPH domains measured by absorption and 
Bradford always corresponded.  Absorption readings at 280 nm detect tryptophan, 
tyrosine and cysteine residues.  The Bradford reagent is thought to detect basic and 
aromatic residues, especially arginine [125], and the BCA reagent detects cysteine, 
tryptophan and tyrosine residues [126].  The DH domain contains 3 tryptophan, 5 
tyrosine, and 4 cysteine residues.  The DHPH domains contain 5 tryptophan, 9 tyrosine, 
and 6 cysteine residues.  There is no consensus on what methods gives the most accurate 
data for protein concentration determination[75].  However, if the concentrations 
determined by 280 nm readings would be correct, our fluorescence assay would show 
that the DH domain has more activity than the DHPH domains and therefore that the PH 
domain has some inhibitory activity.  This is in complete contradiction to what has been 
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found for other RhoGEF PH domains so far, with the exception of the SOS DH/PH 
domains, which do not show any activity in vitro [86].  It would also not be explained by 
structural analysis of the DHPH domains, where the PH domain does not interfere with 
RhoA binding.  
 
Mant-GDP loaded GTPases get lost on re-used Sephadex G-10 gel filtration columns  
Approximately 200 µM of RhoA were loaded with mant-GDP and the 
concentration after gel filtration was 60 to 100 µM for the first two loadings but only 25 
and 10 µM for the subsequent loadings. These concentrations were determined by 
absorption readings at 280 nm.  It might be possible that during the loading process a 
nucleotide free form of RhoA precipitates, binds to the gel filtration column and impedes 
subsequent gel filtration runs.  
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5.  Conclusions and future studies 
The structures of the LARG DH/PH domains alone and in complex with their 
substrate GTPase RhoA were determined.  These structures show the same DH/PH 
domains in its GTPase-bound and -unbound form, and therefore, provide a dynamic view 
of the activation of a GTPase by a RhoGEF.  The structure of the DH/PH domains of 
LARG is the first structure of RhoA selective DH/PH domains and the first of an RH-
RhoGEF subfamily protein.  The structure exhibits novel features (i.e. an αN1/αN2 
subdomain, a hydrophobic patch on the PH domain, different conformation of the 
nucleotide binding site) that might be conserved in the two other RH-RhoGEF family 
members PDZ-RhoGEF and p115RhoGEF, which are all regulated by Gα12/13 proteins.  
The functional relevance of the αN1/αN2 subdomain for nucleotide exchange activity 
has been demonstrated by fluorescence assays using N-terminal mutants of the DH/PH 
domains.   
The role of the RH and PH domains has been investigated with the fluorescence 
assay, using various LARG fragments and mutants.  The functional assays demonstrate 
PH domain-assisted nucleotide exchange in LARG and an inhibitory role of the RH 
domain.  Results from structural and functional analyses taken together allow us to 
generate a model of LARG activation by Gα12/13 at the cell membrane (Figure 5.1) or as 
part of cytoskeleton-attached signaling complexes, that could be applicable to the other 
RH-RhoGEF family members or the larger Lbc subfamily of RhoGEFs.  
However, further structural and functional analyses will need to be performed to 
gain a complete understanding of LARG activity and regulation.  Furthermore, the 
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development of in vivo assays or in vitro assays that better mimic the cellular 
environment in which LARG signaling takes place is inevitable for the understanding of 
LARG activity and regulation in the cell.  
 
The LARG αN1/αN2 subdomain  
 The most distinct structural feature of the LARG DH/PH domains compared to 
other DH/PH domains is its N-terminal αN1/αN2 subdomain, which is seems to be 
important for nucleotide exchange activity, as determined by an in vitro fluorescence 
assay.  An N-terminal deletion mutant decreased the nucleotide exchange activity to only 
20 % of the wild type DH/PH domains.  The αN1/αN2 subdomain of LARG directly 
contacts the RhoA switch I region, which contributes residues to the nucleotide binding 
pocket.  However, it seems that this direct interaction is not critical for nucleotide 
exchange, but rather indirect interactions via the N-terminus of the α1 helix of the DH 
domain.  Glu790 of the α1 helix is fixed in its conformation by a hydrogen bonding 
network with the N-terminal subdomain and packs against Tyr34 in the RhoA switch I 
region.  E790G mutants retain only about 25% of the exchange activity compared to the 
wild type DH/PH domains.  It might be possible that the N-terminal subdomain through 
this indirect interaction with switch I stabilizes the nucleotide-free form of RhoA.  This 
could be either by supporting expulsion of nucleotide by opening the binding pocket 
and/or by relaying changes in the switch I region to other nucleotide binding regions.  
Although such a relay mechanism is not obvious from the structure, the LARG structure 
is the first of a DH/PH-GTPase complex, in which switch I resumes a more open 
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conformation, and where there is interference of the P-loop with the β-phosphate binding 
site and interference of GXKXDL and SAK motif residues with the purine binding site. 
 LARG activity could therefore be regulated via the N-terminal subdomain of its 
DH domain, which could be used as a switch mechanism.  The N-terminal subdomain 
might be a target site for regulation by other proteins (e.g. Gα13) or other domains within 
LARG (e.g. RH, PDZ domains).  For instance the RH domain could sequester the N-
terminal subdomain and therefore leave the DH/PH domains in a less active state.  
Interestingly, LARG constructs that also contain the RH domain (RHDH, RHDHPH) 
show levels of activity that are similar to an N-terminal truncated construct of the DH 
domain.  It can therefore be envisioned that in the resting state of the cell, the RH domain 
binds to the αN1/αN2 subdomain of the DH/PH domains, sequestering it in its less active 
state, where Glu790 is positioned in a less favorable conformation for RhoA interaction.  
Upon activation of Gα12/13 coupled receptors LARG might be recruited to the cell 
membrane by binding of the RH domain to Gα12/13.  This could in turn relieve the 
interaction of the RH domain with the αN1/αN2 subdomain of the DH/PH domains and 
lead to its activation.   
Further structural and functional analyses will be necessary to elucidate the 
function of the αN1/αN2 subdomain and a possible role of the RH domain in regulating 
this subdomain.  Mutants of RhoA-Tyr34 will have to be generated and assessed in the 
fluorescence assay to confirm the possible importance of the Glu790-Tyr34 interface.  A 
structure of the N-terminally truncated DH/PH domains in complex with RhoA might 
trap the DH/PH domains in its less active conformation and the purine and β-phophate 
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binding sites might be un-occupied like in other DH/PH-GTPase complexes, where an N-
terminal subdomain is not present.  A similar result might be seen in a structure of the 
RHDHPH construct in complex with RhoA.  The comparison of KM and kcat values of the 
∆N-DHPH and the wild type DH/PH constructs might be valuable in assessing if the 
subdomain only contributes to the binding of RhoA or also to the catalysis.  Functional 
assays with prenylated RhoA and detergent micelles will be necessary to rule out similar 
contradictory results of RH domain containing constructs that were seen in p115RhoGEF 
when soluble RhoA was used [27].  
 
PH domain assisted nucleotide exchange in LARG 
 The almost invariant position of a PH domain N-terminal to the DH domain in 
RhoGEFs suggests a role for the PH domain in nucleotide exchange.  Although PH 
domain assisted nucleotide exchange in vitro has only been demonstrated for LARG, Dbs 
[4], and Trio [9], it is likely that most RhoGEFs show PH domain assisted nucleotide 
exchange under in vivo conditions.  For example, the intersectin PH domain does not 
contribute to nucleotide exchange in vitro, but is necessary for full exchange in vivo 
[113].  This suggests that the PH domain could be a docking site for either regulatory 
proteins or for regulation by membranes or phospholipids.  Indeed, the LARG structures 
reveal a hydrophobic patch that could be a potential protein docking site.  Furthermore, 
the LARG PH domain has an electrostatic surface potential that is consistent with the 
surface potential of phospholipid binding PH domains, and a possible binding pocket for 
inositol phoshphates between the β1-β2 and β3-β4 loops, comprised of conserved 
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positively charged residues, is present.  The orientation of the phospholipid binding site 
relative to the hydrophobic patch, would allow both, membrane association and 
interaction with a regulatory protein via interaction with the hydrophibic patch at the 
same time.  It can therefore be envisioned that once LARG is recruited to the membrane 
via interaction of its PH domain with membrane located Gα13 and/or phospholipid head 
groups the PH domain is positioned in a more optimal orientation relative to the DH 
domain and RhoA.  In addition to the possible activation via release of the N-terminal 
subdomain (see above) this would provide a mechanism to even further enhance the 
activity of LARG (Figure 5.1).  Another possibility is that the LARG PH domain binds to 
filamentous actin (F-actin).  For instance the PH domain of Bruton’s tyrosine kinase 
(Btk) binds to F-actin via a region that is overlapping with its inositol binding site [80].  
The hydrophobic patch of LARG could at the same time bind to another actin binding 
protein.  The possibility that the LARG PH domain is regulated by Gα13 and/or 
phospholipid binding could be investigated by employing an adapted fluorescence assay 
with prenylated RhoA and lipid vesicles.  Furthermore, binding studies of various LARG 
fragments with Gα13 could confirm the proposed model and in the long term allow the 
crystallization of an LARG fragment in complex with Gα13.  These experiments require a 
source for the large scale production of Gα13, which is currently not available (see 
Chapter 2).  
A high degree of flexibility of the DH-PH junction has been demonstrated by our 
structures, where, upon complex formation, the PH domain rotates by about 30° relative 
to the DH domain to engage in RhoA binding.  Two contact regions between the PH 
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domain and RhoA were identified in the complex structure.  The first one is a direct 
contact between Ser1118 in the αCT helix of the PH domain and RhoA-Glu97.  The second 
contact region is an indirect contact in the hinge region between the DH and PH domains, 
where PH domain residues support contacts of the DH domain with RhoA-Arg68.  The 
importance of residues in the hinge region between the DH and PH domains has been 
demonstrated by the loss of PH domain-assisted nucleotide exchang in the Glu1023 
mutants.  Glu1023 is the central residue in a hyrdogen bonding network between DH 
domain residues (Phe990, Arg986), PH domain residues (Phe1039) and RhoA residues 
(Arg68).  The direct contact between the PH domain and RhoA (LARG Ser1118-RhoA 
Glu97) does not seem to be important for nucleotide exchange in vitro, since a RhoA 
E97A mutant is an equally good substrate of LARG as wild type RhoA.  However, this 
does not exclude the possibility that this direct contact contributes to PH domain-assisted 
nucleotide exchange in vivo, similarily to the direct PH domain-Cdc42 contact in the Dbs 
structure (Dbs L885-Cdc42 His103).  A Dbs K885A mutant had unchanged exchange 
activity in vitro [4] but lost about 30% of its transforming ability [88].  To investigate the 
functional relevance of PH domain assisted nucleotide exchange in LARG it is therefore 
necessary to test the PH domain mutants in either in vivo assays or in vitro assays that 
better mimic an in vivo environment.  The fluorescence assay described in Chapter 4 
could be adapted to conditions that better mimic an in vivo environment by using 
prenylated RhoA and lipid vesicles.  For p115RhoGEF it has been shown that prenylated 
RhoA is a much more potent substrate [27].  This might be due to either contribution of 
the prenyl group to protein-protein interactions, or the RhoGEF might be positioned on 
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the surface of the lipid vesicles in a manner that is more optimal relative to the orientation 
of prenylated RhoA on these vesicles.  Using this adapted assay might allow the detection 
of the importance of the Ser1118-Glu97 interaction.  It would also be interesting to 
investigate a possible activation of the LARG DH/PH domains by phospholipid head 
groups, which could be used in the lipid vesicles.  However, activation of nucleotide 
exchange on GTPases by phospholipids has been observed [127] and appropriate controls 
therefore have to be taken.   
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Figure 5.1:  A model of signaling from LARG to RhoA, based on the structures of 
the LARG DH/PH domains and their complex with RhoA (see Chapter 3), as well as 
on functional assays of RhoA and LARG mutants (see Chapter 4).  In the resting state 
of the cell the LARG DH/PH domains are in a less active conformation, due to 
sequestering of the αN1/αN2 subdomain by the RH domain.  Activated Gα13 could 
release this interaction by binding to the RH domain.  This could result in the 
transformation to the more active conformation, where a more compatible surface for the 
binding of RhoA is available.  At the same time the PH domain could assume a more 
compatible position for the binding of RhoA, due to its interaction with either Gα13 or 
membrane phospholipids or both.   
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